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ABSTRACT
In the United States, ischemia resulting from cardiovascular disease and acute
trauma affects nearly 50% of all adults. Therapeutic angiogenesis aims to stimulate
the formation of new microvasculature that alleviates hypoxia, reduces tissue
morbidity, and improves wound healing. The current primary therapeutic approach
is vascular endothelial growth factor (VEGF) injection therapy but is hindered by
several challenges. Consequently, bioactive small molecules are being used to target
hypoxia-inducible factor-1α (HIF-1α), the master regulator of oxygen-sensing
pathways that is responsible for activating angiogenesis in response to tissue
hypoxia. However, successful clinical translation of small molecules for therapeutic
angiogenesis still faces several challenges including drug solubility, administration
route, and biodistribution. The objective of this project was to develop a scaffold to
activate and support therapeutic angiogenesis through local delivery a proangiogenic small molecule from a bioactive hydrogel matrix.
N-oxalylglycine (NOG) is a known HIF-1α stabilizer that works by
outcompeting the HIF-1α destabilizing co-factor 2-oxoglutarate for its binding site
and prevents the eventual degradation of HIF-1α. We first synthesized a new
macromolecular prodrug conjugate of hyaluronic acid with NOG (HA-NOG). Free NOG
was released from HA-NOG in a sustained manner in the presence of enzymes
(hyaluronidases and esterases) and released NOG stimulated HIF-1α nuclear
accumulation, target gene expression, as well as in vitro endothelial cell
tubulogenesis. We then evaluated NOG release kinetics and bioactivity from PEG-
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based monolayer and bilayer hybrid hydrogels incorporating the HA-NOG conjugate
in vitro, and found that sustained, local release of NOG from a hydrogel delivery
system could increase HIF-1α target gene expression. Previous work from the lab
utilized a PEG diacrylate (PEGdA)/HA hybrid semi-interpenetrating network (semiIPN) hydrogel as a carrier for an HA-based macromolecular prodrug. This hydrogel
was effective in sustained release but limited in innate bioactivity to support cellular
invasion and remodeling. Therefore, we investigated increasing the concentration of
modified naturally derived polymers, gelatin methacrylate (GelMA) and glycidyl
methacrylate HA (GMHA), in PEGdA-based hybrid hydrogels. We first created a new,
shortened method for purifying GelMA by acetone precipitation. The subsequent
hybrid copolymer hydrogel formulation consisted of covalently crosslinked PEGdA,
GelMA, and GMHA. Several formulations of the new bioactive PEGdA/GelMA/GMHA
hybrid hydrogel demonstrated strong mechanical properties, while also supporting
increased cell spreading and migration relative to the previous PEGdA/HA semi-IPN
formulation.
Overall, the results of this work present a potential new treatment option for
ischemic injuries by safely and effectively delivering pro-angiogenic NOG from hybrid
hydrogel matrices, as well as show the improved bioactivity of a newly synthesized
PEGdA/GelMA/GMHA hybrid hydrogel. In the future, this drug delivery system will
be evaluated in rodent central nervous system injury models to assess functional
recovery.
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CHAPTER ONE
REVIEW OF LITERATURE

1.1 OXYGEN HOMEOSTASIS AND ISCHEMIA
1.1.1 Normoxia and the Role of Oxygen
The body typically operates in a normoxic environment, where there are normal
levels of oxygen to allow the day-to-day operation of bodily systems. Normoxic
conditions for the human body range between 10-21% oxygen concentration for the
intracellular environment 1. Sustaining a normoxic environment is critical for the
body to function properly and if not sustained, can cause adverse events. When the
normal oxygen level falls below the normoxic range (<10% oxygen), hypoxia occurs
1.

One function that is affected by hypoxia is cellular metabolism. Mitochondria use

oxygen for oxidative phosphorylation in the production of adenosine triphosphate
(ATP). When intracellular cellular oxygen levels are reduced, glycolysis is initiated to
produce ATP and metabolic process does not go through oxidative phosphorylation
2.

Glycolysis cannot be maintained for long periods of time because of build-up of

potentially harmful by-products like lactic acid 3. The ATP produced in both pathways
is the energy source used by many of the systems of the body to carry out everyday
functions, including blood circulation and movement.
1.1.2 Ischemic Pathology
Ischemia, or lack of blood flow, stems from injured blood vessels or vascular
occlusions. Ischemic injuries lead to hypoxia that can also cause cell necrosis and
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additional damage to the surrounding tissue or result in severe organ damage from
lack of adequate ATP and buildup of metabolic waste 4–7. Major pathologies that can
occur due to ischemia include peripheral vascular disease that can lead to stroke and
myocardial infarction 2. Additionally, ischemia plays a prominent role in the
progression of chronic wounds, like diabetic, pressure, and neuropathic ulcers, and
can eventually lead to reperfusion injury upon return of blood flow 7,8. Local hypoxia
in cell transplantation presents a major barrier to cell therapy as a potential
treatment option, as the transplanted cells undergo the same anaerobic processes in
response to hypoxia, leading to cell necrosis as mentioned above. Current treatments
of ischemic pathologies are limited and mostly aim to dilate blood vessels or reduce
clotting. Therapeutic angiogenesis, a process of stimulating microvessel formation by
controlling exogenous actions of the angiogenic pathway, offers potential as a
treatment for ischemic injury 9. This process can be applied to improve wound healing
by accelerating revascularization in damaged tissue, making it an attractive choice for
tissue engineering and regenerative medicine applications 9,10.
1.1.3 Cellular Response to Hypoxia
1.1.3.1 Hypoxia-Inducible Factors
Hypoxia has been shown to help activate the transcription factor, HIF 11. HIF
is a heterodimer with two subunits, HIF-α and HIF-β, where HIF-α responds to
changes in available oxygen and HIF-β regulates the Aryl hydrocarbon nuclear
translocator family

11.

Additionally, HIF-α has three subunits, HIF-1α, HIF-2α, and

HIF-3α, while HIF-1α and HIF-2α are known to be regulators of oxygen-dependent
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pathways. Each is a basic helix-loop-helix (bHLH) protein with oxygen-dependent
degradation domains (ODDD) consisting of an N-terminal transactivation domain (NTAD)

12,13.

The ODDDs on each HIF-α subunit are the locations containing prolines

that serve as hydroxylation points for degradation, while the N-TAD allows binding
of nuclear coactivators for transcription 13,14. HIF-1α and HIF-2α contain C-terminal
transactivation domains (C-TAD), while HIF-1β contains a general transactivation
domain (TAD)

12,14.

The C-TAD contain asparagine that also serve as hydroxylation

points for the inactivation of the subunits and, similar to the TAD on HIF-1β, are also
binding sites for transcriptional coactivators 13,14. Both HIF-1α and HIF-2α play a role
in angiogenesis and even have several overlapping target genes, but mostly reside in
different tissues, with HIF-1α expressed in endothelium and HIF-2α expressed mostly
in parenchyma and interstitium 15–17. There is still much unknown about HIF-3α but
it has been widely accepted that this subunit inhibits both HIF-1α and HIF-2α 18.
1.1.3.2 Stabilization/Destabilization of Hypoxia Inducible Factor-1α
HIF-1α is generally considered the master regulator of gene expression
associated with hypoxia. It was the first of the HIF-α subunits to be identified and is
linked to several important physiological pathways. In a normoxic environment, HIF1α is typically marked for degradation by prolyl hydroxylase domains (PHDs) and the
von-Hippel-Lindau (VHL) ubiquitin ligase complex

19.

PHDs are 2-oxoglutarate (2-

OG), Fe+2, and oxygen (O2)-dependent hydroxylases. One of the PHD complexes, prolyl
hydroxylase domain 2 (PHD2), works as a feedback inhibition mechanism as it is
activated by the presence of HIF-1α 19. PHD2 marks HIF-1α with a hydroxyl group on
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either Pro402 or Pro564 of the oxygen-dependent degradation domain (ODDD),
initiating the degradation process 19. The addition of a hydroxyl group onto HIF-1α
allows for it to be recognized by the VHL-ubiquitin ligase complex, which then tags
HIF-1α with ubiquitin 19. The newly added ubiquitin signals proteasomes to degrade
HIF-1α. In addition to PHDs and the VHL-ubiquitin ligase complex, factor-inhibiting
HIF (FIH) also works to inhibit the normal function of HIF-1α. FIH, like the PHDs, is a
2-OG, Fe+2, and O2-dependent hydroxylase that adds a hydroxyl group to HIF-1α.
Unlike the PHDs, however, FIH adds a hydroxyl group to an asparagine on HIF-1α at
Asn803 of the C-terminal transactivation domain (CTAD) 11. This additional hydroxyl
group blocks the site at which adenovirus E1A-binding protein p300 (p300) binds
HIF-1α 11. The processes of HIF-1α degradation and inhibition by PHD2 and FIH can
be seen in Figure 1.1 and Figure 1.2, respectively.

4

Figure 1.1. Pathway for HIF-1α degradation by prolyl hydroxylase domain 2 (PHD2)
and the von Hippel Lindau (VHL) ubiquitin ligase complex. PHD2 adds a hydroxyl
group to a proline on HIF-1α, which causes binding to the VHL complex. HIF-1α is
then marked with ubiquitin for degradation.

5

Figure 1.2. Pathway for HIF-1α inactivation by factor inhibiting HIF-1 (FIH). FIH adds
a hydroxyl group to an asparagine on HIF-1α. This blocks the binding site for the HIF1α co-activator, adenovirus E1A-binding protein p300 (p300). Blocking the binding
site causes HIF-1α to become inactive.

1.1.3.3 Hypoxia Inducible Factor-1α Target Genes
Upon translocating to the nucleus, HIF-1α binds with HIF-1β to form the
complete HIF-1 complex. This complex also interacts with co-activators to initiate
transcription of angiogenic growth factors 20. Initial contact of the HIF-1 complex with
hypoxia-responsive elements (HRE) begins the transcription process. After binding
to HRE, the HIF-1 complex recruits co-activators to transcribe specific target genes.
6

Some of the known co-activators of the HIF-1 complex transcriptional activity are
CREB-binding protein (CBP), steroid receptor co-activator (SRC), and p300 12. Each
of these co-activators plays an important role in transcribing target genes. CBP and
p300 are known to bind to the N-terminal transactivation domain (N-TAD) of HIF-1α,
spanning to the transactivation domain (TAD) of HIF-1β

21.

The way these co-

activators bind to HIF-1α can be seen in Figure 1.3. CBP and p300 tend to work
closely and bind to similar areas along the HIF-1 complex to promote the expression
of the target genes erythropoietin (EPO) and VEGF 22. SRC is another co-activator that
interacts with the HIF-1 complex to help transcribe target genes associated with
angiogenesis. SRC-1, one of three forms of SRC, directly influences HIF-1α, as
overexpression of SRC-1 correlates to higher concentrations of HIF-1α within the
nucleus of a cell 23.

7

Figure 1.3. Pathway for gene activation by HIF-1α upon translocating to the nucleus.
HIF-1α binds with HIF-1β forming the HIF-1 complex. This binds to the hypoxiaresponsive element (HRE), which recruits the p300/CREB-binding protein (CBP)
complex and steroid receptor co-activator-1 (SRC-1). Target genes are then activated
for transcription.

The co-activators described above allow for HIF-1α to transcribe particular
target genes. These target genes encode proteins in the VEGF pathway that include
VEGF, EPO, transferrin (TF), and nitric oxide synthase 3 (NOS3), as seen in Figure

8

1.4. These four proteins all work to stimulate increased oxygen delivery in different
ways. NOS3 is the main protein that works to promote vascular tone in order to
ensure proper function of microvessels 24. TF works with a protein called transferrin
receptor (TFRC). When TF binds to iron, it can then transport it to TFRC in order to
get the process of iron metabolism started. This process is necessary to shuttle iron
to the bloodstream 25. EPO is the chemical factor that stimulates increased production
of red blood cells in the body. This is critical in times of hypoxia, as the lack of oxygen
in the body will require an increased amount of red blood cells to transport the
oxygen that is available

26.

The last of the mentioned proteins, VEGF, is the most

critical for increasing oxygen delivery to areas of the body affected by hypoxia. VEGF
is a critical growth factor that activates endothelial cells to initiate the first steps in
the process of angiogenesis that leads to the formation of new microvessels.

9

Figure 1.4. Outcome of activated target genes for angiogenesis. Vascular endothelial
growth factor (VEGF) induces the formation of microvessels. Erythropoietin (EPO)
causes an upregulation of red blood cells. Transferrin (TF) helps start the metabolism
of blood-based iron. Nitric oxide synthase 3 (NOS3) promotes vascular tone for
proper microvessel function. All this help to increase the delivery of blood and the
components within blood through angiogenic microvessels.

1.1.3.4 Activation of Vascular Endothelial Growth Factor Receptor
VEGF has seven different constituent types, VEGF-A, VEGF-B, VEGF-C, VEGF-D,
VEGF-E, VEGF-F, and PIGF, each working to perform a specific task. The VEGF type
that is most typically involved with angiogenesis is VEGF-A 27,28. VEGF-A also has a set
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of subtypes, all of which function differently, VEGF-A121, VEGF-A145, VEGF-A148, VEGFA165, VEGF-A183, VEGF-A189, and VEGF-A206

29.

VEGF-A165 has been shown to be the

most readily available and most important for angiogenesis 30. Along with the seven
VEGF types, there are also several variants of the VEGF receptor (VEGFR) that can
bind to specific VEGF types. The receptors of VEGF are VEGFR1, VEGFR2, and
VEGFR3, where VEGFR1 and VEGFR2 bind with VEGF-A 31. VEGFR1 and VEGFR2 fall
into the category of receptor tyrosine kinases (RTKs). Both of the receptors are
expressed by endothelial cells and are integral components in the promotion of
angiogenesis. The binding of VEGF-A to VEGFR1 can lead to vascular endothelial cell
migration and vascular permeability. VEGF-A binding to VEGFR2 leads to endothelial
cell migration and vascular permeability (as a complementary response to VEGFR1),
and cell survival and proliferation 32. The combination of responses from VEGFR1 and
VEGFR2 are necessary for the body to start undergoing angiogenesis. A simplified
representation of the VEGF/VEGFR pathway can be found in Figure 1.5.
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Figure 1.5. Receptor-ligand interaction between vascular endothelial growth factorA (VEGF-A) and vascular endothelial growth factor receptor-1 and -2 (VEGFR1 and
VEGFR2). VEGF-A can bind to both VEGFR1 and VEGFR2 to induce endothelial cell
migration, proliferation, survival, and vascular permeability en route to promoting
angiogenesis.

1.1.3.5 Activation of Additional Angiogenic Factors

12

In addition to VEGF, EPO, TF, and NOS3, HIF-1α has also been shown to
increase the expression of other angiogenic factors. These angiogenic factors exist to
help move the process of angiogenesis to completion and include fibroblast growth
factor (FGF), platelet-derived growth factor (PDGF), ephrin, and angiopoietin. The
most notable of these additional angiogenic factors is bFGF. This growth factor is the
starting point of a cascade that helps to create new blood microvessels and ensure
their stability during the maturation process

33.

bFGF stimulates local endothelial

cells to produce plasminogen activators, typically involved in the breakdown of blood
clots 33. The plasminogen activators help to degrade the basement membrane of the
existing blood vessel so that cells can enter the matrix surrounding the vessel.
Additional cells will migrate to the site and proliferate, differentiating into cells that
form the new lumen-containing microvessel. These newly differentiated cells form a
new basement membrane, which releases PDGF. The release of PDGF attracts
pericytes, contractile cells within vasculature, to help with maintaining the stability
of the microvessel

34.

This process involves the use of angiopoietin-1 for vascular

maturation and angiopoietin-2, which usually leads to cell death but promotes neovascularization when in the presence of with PDGF

34.

Along with angiopoietin,

ephrins are involved in the angiogenic process by binding with ephrin receptors to
guide new blood microvessels in cell-cell contact and cell adhesion

35.

The

culmination of outcomes from the HIF-1α pathway involving the VEGF and bFGF subpathways drives the overall process of angiogenesis, helping in the creation, stability,
and viability of the newly formed blood microvessels.
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1.1.4 Cell/Tissue Physiology
In order to achieve new microvessel formation, cells need to go through three
distinct phases: quiescence, activation, and branching 36,37. The quiescence phase is a
constant state characterized by the maintenance of endothelial cells by levels of VEGF,
ANG-1 and FGF that are present always. A secondary cell type, pericytes, act to
suppress the differentiation of endothelial cells and aid in their survival to maintain
the basement membrane. Both endothelial cells and pericytes work to maintain the
basement membrane of vessels, but are also supported by collagen, laminin, and
fibrin

36.

When elevated expression levels of VEGF, FGF, and ANG-2 are present,

endothelial cells become activated. This activation phase is typically caused by
hypoxia, either due to injury or from an ischemic pathology. Whereas ANG-1 is crucial
for the maintenance of endothelial cells in vessels, the presence of ANG-2 signals
pericytes to begin detaching from the basement membrane by matrix
metalloproteinases (MMPs)

38.

The final phase of microvessel formation and

stabilization is branching, where new extracellular matrix (ECM) is deposited to begin
attracting nearby endothelial cells to form new microvessel branches. With the
increased presence of growth factors, a gradient is formed that tip cells can follow to
elongate the newly formed branches. Stalk cells closely follow the tip cells and form
the length of the new microvessel that is eventually connected to an existing branch.
As this connection is happening, newly formed basement membrane is being
stabilized along the new branch, with blood flow resuming once endothelial cells and
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pericytes stabilize the microvessel in response to PDGF, ANG-1, and transforming
growth factor-β (TGF-β).
1.1.5 Dangers of Overactivation/Stabilization
HIF-1α is a master transcription factor of not only the angiogenic
process/oxygen homeostasis, but of several other pathways, as well, including
glycolysis, cell proliferation, collagen production, apoptosis, metastasis/invasion, and
epithelial to mesenchymal transition (EMT) pathways

21,39.

Because HIF-1α is

connected to many other pathways and processes, its stabilization may cause adverse
events if it is not regulated properly. One of the most notable side effects of extended
HIF-1α stabilization is tumorigenesis, or formation of tumors 40. A study performed
by Talks et. al. revealed that in tumors originating from human colon, pancreatic,
prostate, breast, bladder, glial, ovarian, and renal tumors, there was an increase in
HIF-1α expression, as well as HIF-2a

41.

Tumorigenesis, although interchangeably

used with carcinogenesis, does not always lead to malignant tumor formation, but
this idea may not hold true for HIF-1α-induced tumor formation. HIF-1α stabilization
has been linked to cancerous tumor formation, but shows very little expression in
benign tumors, increasing the risk of overstabilization/overactivation of the HIF
pathway 42–44. Therefore, appropriate HIF-1α stabilization is crucial for not crossing
the therapeutic-tumorigenic threshold.
1.2 THERAPEUTIC ANGIOGENESIS
1.2.1 Broad Review of Therapeutic Angiogenic Techniques
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The induction of therapeutic angiogenesis as a treatment for ischemic injuries
is an ongoing endeavor by researchers to find the optimal method for universal
microvessel formation. Current techniques for stimulating angiogenesis include
growth factor injection and gene delivery therapies, with VEGF being the most
commonly injected/delivered growth factor, given its prominent role in the
angiogenic process. Growth factor therapy using VEGF presents several challenges,
including the lack of long-term microvessel maturation 45,46. As an alternative, several
groups have explored delivery systems incorporating two or more angiogenic factors
with different release kinetics

47,48.

Despite encouraging results, growth factor

therapy still faces substantial challenges due to the short half-life of many growth
factors in tissue and their instability during processes with biomaterial-based
carriers, leading to the need for supraphysiological dosing with associated high costs
and risks of adverse side effects 46,48,49. Additionally, delivery of exogenous HIF1A and
VEGF genes have been used in gene therapy to stimulate microvessel formation, but
with limited success

50,51.

Gene delivery is an efficient method of overproducing a

desired protein, but this overproduction can lead to tumor formation and, in some
cases, organ failure 9,50. Another technique for inducing therapeutic angiogenesis is
through cell therapy utilizing progenitor cells, with the goal of influencing
differentiation into blood vessel-related cell types. Studies using bone marrow stem
cells (BMSCs) and endothelial progenitor cells (EPCs) yielded increased blood flow,
but these were results were diminished by the lack of cell survival and the magnitude
of cells needed to produce such an angiogenic response
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52.

Alternatively, small

molecule stabilization of HIF-1α is becoming a promising option for targeting the
angiogenic pathway with several identified therapeutics capable of regulating proangiogenic gene expression.
1.2.2 Rationale for Small Molecule Drugs
Small molecules are stable in physiological environments, but much like genes
and proteins, are typically delivered systemically and are susceptible to premature
clearance from the body if they are not properly delivered. Since small molecules are
synthetically derived, most contain terminal functional groups that can be used for
functionalization to scaffolds or macromolecules, increasing their stability, retention
time, and ability to be locally administered 53. These traits make small molecules an
exciting and attractive option for stimulating therapeutic angiogenesis, with many
known HIF-1α stabilizers already being studied.
1.2.3 HIF-1α Stabilizers
The idea behind understanding what subcellular complexes are involved with
angiogenesis is to be able to find ways to exploit the pathways for targeted
enhancement of wound healing or treatment of ischemic pathology. The use of
growth factors for this application has been explored but has not been successful 27.
Since each growth factor associated with angiogenesis serves a specific function, it is
not likely that there would be a complete and functioning blood microvessel by
utilizing only one of them

27.

Instead, specific small molecules have been found to

interfere with some of these pathways 54. Manipulating the HIF-1α pathway, or parts
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of the pathway, can allow investigators to induce therapeutic angiogenesis in a
localized area.
Because angiogenesis leads to microvascular formation, which is synonymous
with elevated levels of blood-based healing factors through a targeted area, small
molecules that can induce a state similar to hypoxia are desirable when trying to
increase the ability to heal wounds. Therapeutic small molecules that act as iron
chelators or 2-oxoglutarate competitive analogues have been shown to inhibit PHD
and FIH activity, leading to HIF-1α stabilization, activation of pro-angiogenic gene
expression, and improved vascularization in several animal models 55–57.
Small molecule activators of HIF-1α can be sorted into groups based on their
composition and mechanisms of activation

54.

The most general groups of small

molecules are iron chelators and 2-oxoglutarate analogues. In addition to the more
common HIF-1α activators, there are novel small molecules that have been tested as
HIF-1α activators. Many of the novel small molecules do not activate HIF-1α as
effectively as some of the other known compounds and, as such, have been
disregarded for therapeutic use

54.

A list of many known HIF-1α activators can be

found in Table 1.1.
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Table 1.1. Small molecule activators of the HIF-1α pathway.
Activators of HIF-1α
Category

Alkaloids/Amino
Acid derivatives

Phenolic compounds

Steroids

Metabolic products

Synthetics

Metals/Miscellaneous

Name

Inhibition Method

Desferrioxamine
Desferri-exochelin DFE 722 SM
Ciclopirox olamine
8-methyl-pyridoxatin
N-oxalylglycine
Dimethyl-oxalylglycine
3-hydroxypyridine-2-carbonyl-glycine
3,4-dihydroxybenzoate
Pyridine-2,5-dicarboxylate
N-oxalyl-2S-alanine
Alahopcin
Dealanylalahopcin
3-carboxymethylene N-hydroxy succinimide
3-carboxy-N-hydroxy pyrollidone
S-nitroso-N-acetyl-D,L-penicillamine
S-nitrosoglutathione
Diazen-1-ium-1,2-diolate
Spermin NONOate
Vinblastine
Colchicine

Iron chelator
Iron chelator
Iron chelator
Unknown
2OG competitor
2OG competitor
Selective PHD
Selective FIH
Selective FIH
2OG competitor
2OG competitor
2OG competitor
Selective PHD
Selective PHD
NO donor/Bind iron/Block O2
NO donor/Bind iron/Block O2
NO donor/Bind iron/Block O2
NO donor/Bind iron/Block O2
Microtubule disruption
Microtubule disruption

Dibenzoylmethane
Quercetin
Epicatechin-3-gallate
Epigallocatechine-3-gallate
Pycnidione
4-hydroxy estradiol
Dihydrotestosterone
Phorbol 12-O-myristate 13-acetate
Glucose
Pyruvate
Lactate
Oxaloacetate
Succinate
2,2’-pyridyl
1,10-phenanthroline
Methyltrienolone
Nocodazole
Tilorone
Cobalt
Nickel
Chromium (VI)
Copper
Mersalyl

Selective PHD
FIH/PHD inhibition
Iron chelator
Iron chelator
HRE stabilization
PI3K/AKT/mTOR activation
PI3K/AKT/mTOR activation
Pathway modulation
Prevent degradation
Prevent degradation
Prevent degradation
Prevent degradation
Selective PHD
Iron chelator
Iron chelator
PI3K/AKT/mTOR activation
Microtubule disruption
Unknown
Iron competitor
Iron competitor
Iron competitor
Iron competitor
MAPK activation
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1.2.3.1 Iron Chelators
Iron ions (Fe+2) are particularly important for regulation of the HIF-1α
pathway because of the HIF-1α inhibiting, Fe+2-dependent hydroxylases, PHD and
FIH. Some of the small molecules discovered to help with the activation of HIF-1α are
iron chelators. Iron chelators are molecules that can bind to iron ions that are not
bound to any other molecules 58. By binding to the iron necessary for PHD and FIH
enzyme activity, iron chelators leave the conformation of the HIF-1α inhibitors
unchanged. This inhibits the binding of HIF-1α that usually leads to its degradation
59.

Some well-studied iron chelators are outlined in greater detail below.
One of the first iron chelators discovered to cause HIF-1α not to be degraded

under normoxic conditions is desferrioxamine. Desferrioxamine, a strict Fe+2 iron
chelator, can inhibit the HIF-1α pathway by binding with the iron that typically acts
as a cofactor to PHD and FIH

58.

Studies have shown that by introducing

desferrioxamine into an in vitro or an in vivo model, there will be an increase in HIF1α-induced gene expression

60,61.

These studies looked at HIF-1α upregulation in

bone and brainstem injury repair, as well as angiogenesis. Another study
administered desferrioxamine and observed the activity from applying the small
molecule to mouse bone marrow mesenchymal stromal cells. Again, the results
showed that there was an increase in HIF-1α expression and, subsequently,
angiogenesis 62. It has been reported, however, that the use of desferrioxamine can
cause adverse side effects, including renal insufficiency, neurotoxicity, and

20

hypotension

63.

This report comes from an in vivo study of desferrioxamine

administered through local intramuscular injection.
Another common iron chelator that has been used in studies related to HIF-1α
is ciclopirox olamine. Ciclopirox olamine, a strict Fe+2 iron chelator, has previously
been, and is currently, used as a treatment option for those with toxic levels of iron
64.

Because of its ability to bind iron so well, it was then translated to regenerative

medicine for angiogenic promotion. This compound has been shown to be more
potent in its ability to activate HIF-1α than desferrioxamine, despite having similar
activation methods

54,65.

These same studies showed that ciclopirox olamine can

induce similar HIF-1α activity with a concentration about 10 times less than that of
desferrioxamine. The difference in the affinities for iron between ciclopirox olamine
and desferrioxamine could be explained by ciclopirox olamine’s greater lipophilic
properties. However, this isn’t supported since 2,2’-dipyridyl, another iron chelator,
is also highly lipophilic but shares a similar potency to desferrioxamine 65.
As mentioned above, 2,2’-dipyridyl is a strict Fe+2 iron chelator that has also
been studied in relation to the regulation of HIF-1α and the promotion of
angiogenesis. A study performed by Linden et al. showed that 2,2’-dipyridyl had an
optimal concentration for inducing HIF-1 target gene expression at slightly less than
10 times the optimal concentration of ciclopirox olamine (150μM vs. 16μM)

65.

Another study performed by Hamadian et al. showed that introducing 2,2’-dipyridyl
into cell cultures leads to increased stabilization of both HIF-1α and HIF-2α, while
also increasing expression of HIF2A mRNA and decreasing expression of HIF1A

21

mRNA, similar to hypoxia 66. 2,2’-dipyridyl is a much more membrane permeable iron
chelator than desferrioxamine, giving it certain properties that make it more
desirable for stabilizing HIF-1α and triggering angiogenesis 58. Cho et al. showed the
difference in cell membrane permeability by measuring HIF-1α stabilization in vitro
and comparing it against stabilization of in vivo 58.
Another strict Fe+2 iron chelator that has been identified as a molecule for
inducing HIF-1α stabilization is 1,10-phenanthroline. 1,10-phenanthroline has been
shown to be a strong inhibitor of dioxygenases, the category of proteins that describe
the prolyl hydroxylase domains 67. In a study aiming to show compounds that inhibit
HIF-1α, 1,10-phenanthroline was used a control to see if the inhibitory compounds
could overcome its effects. The results showed that, despite the inhibitory
compounds successfully inhibiting HIF-1α during physical hypoxia, they could not
negate the effects of 1,10-phenanthroline-induced pseudo-hypoxia. The VEGF
expression stimulated by 1,10-phenanthroline exposure was found to be higher than
that of physical hypoxia 68. Another study of 1,10-phenanthroline discovered that itl
induced the same responses as physical hypoxia but was not restricted to the HIF-1α
pathway 69. This is troublesome for applications that want to target angiogenic factors
and not impact other pathways, like collagen formation.
A well-known activator of the HIF-1α pathway is cobalt, but more specifically,
cobalt chloride and cobalt sulfate. Cobalt has long been used as an inhibitor of PHD
enzymes. This is because of its ability to bind to the iron-binding portion of the prolyl
hydroxylase and render it inactive for inhibiting HIF-1α
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70.

If HIF-1α does become

hydroxylated by PHD2, the cobalt can bind to the PER-ARNT-SIM (PAS) motifs of the
hydroxylated HIF-1α and prevent its degradation by the von Hippel Lindau ubiquitin
ligase complex

71.

Cobalt chloride has been used in many studies as a control to

produce a pseudo-hypoxic response in order to compare other HIF-1α activators
against it. This is because of the reliability of cobalt chloride to mimic hypoxia in cells
while also having the ability to increase VEGF expression on a similar level to physical
hypoxia 72. Cobalt sulfate can be used as a HIF-1α activator as well and produces VEGF
expression levels similar to cobalt chloride.
1.2.3.2 2-Oxoglutarate Analogues
Another major class of HIF-1α activators include those that are structurally
similar to, 2-oxoglutarate. Analogues of 2-oxogultarate can activate the HIF-1α
pathway by competitively antagonizing 2-oxoglutarate, an essential co-factor of
PHD2 and FIH. Since these analogues are used to outcompete 2-oxoglutarate for the
binding sites on PHD2 and FIH, their concentration must then be larger than that of
2-oxoglutarate 54.
L-mimosine is a 2-oxoglutarate analogue that has been studied for its
effectiveness as a competitive antagonist of 2-oxoglutarate on prolyl hydroxylase 73.
A study by Warnecke et al. showed that L-mimosine was an effective inhibitor of
PHD2 at a concentration of 100μM 74. Another study showed that L-mimosine induced
expression of VEGF at a level that is 2-fold higher than expression induced by physical
hypoxia

75.

Despite these findings, L-mimosine can have significant cytotoxic side

effects if used at concentrations above 400μM 74. This has raised concerns for its use

23

in clinical applications, as it could inadvertently cause further damage if not
appropriately dosed.
3,4-Dihydroxybenzoate is another compound that will competitively
antagonize 2-oxoglutarate on PHD2 and FIH. As with the other PHD2 inhibitors, 3,4dihydroxybenzoate also stimulates the activation of HIF-1α. Its effectiveness as an
activator of HIF-1α by inhibition of PHD2, however, has been shown to be less than
optimal compared to other compounds 62. 3,4-Dihydroxybenzoate has been shown to
be more effective at inhibiting FIH than PHD2, which also allows HIF-1α to avoid
inhibition 54,76. A study by Han et al. discovered that the transcription levels of HIF-1α
did not change but, instead, the HIF-1α proteins levels changed, causing a
downstream

accumulation

that

could

impact

gene

expression

77.

3,4-

Dihydroxybenzoate has also been used as a preconditioning agent in studies looking
at ways to improve injury induced by hypoxia. In these types of studies, 3,4dihydroxybenzoate upregulates the expression of VEGF, giving it properties desirable
for induced microvascular formation 78.
N-oxalylglycine (NOG), another analogue of 2-oxoglutarate, was specifically
designed to inhibit PHD2. Through further studies of the compound in relation to HIF1α, it was discovered that NOG is actually a stronger inhibitor of FIH than PHD2 58,76.
FIH tends to be harder to inhibit than PHD2 in the HIF-1α pathway because it can still
function at lower levels of oxygen 79,80. A study performed by Cho et al. showed that
NOG had an inhibitory capacity on FIH that was 35 times stronger than that on PHD2
58.

It is because of this that NOG is a more effective activator of the HIF-1α pathway
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than most of the other compounds identified above. The activation of HIF-1α has been
linked to expression of not only VEGF but also EPO. A study by Volke et al. showed
that HIF-1α activation by NOG induces very limited expression of EPO despite
showing a high expression of VEGF

81.

The ability of NOG to be more specific in its

activation of target genes could allow for better control of intracellular pathways
when trying to induce specific cellular responses.
Another 2-oxoglutarate analogue, DMOG, is the dimethyl ester of NOG and has
been studied extensively for use in various therapeutic applications involving
microvascular formation. DMOG can effectively penetrate cells to inhibit PHD2 and
FIH from hydroxylating HIF-1α to initiate its degradation and inhibition, respectfully
82.

A study by Jaakkola et al. showed that cells exposed to DMOG under normoxic

conditions accumulated HIF-1α more rapidly than those exposed to physical hypoxia
82.

The potential uses of DMOG range from healing tissue after myocardial injury to

providing neuroprotection from occlusion of the cerebral artery

83.

DMOG has also

been tested in bone regeneration studies to see if the upregulation of angiogenic
factors VEGF and EPO would have an effect on the healing time of a fracture. Results
from one of these studies showed that when DMOG was injected at the site of a
fracture, there was significant improvement in bone healing as compared to intrinsic
bone healing

83,84.

DMOG has been proven to be an effective therapeutic agent for

activating the HIF-1α pathway but has also been shown to cause toxicity in cells.
Because DMOG is such a potent, cell-penetrating compound, it could possibly cause
unwanted side effects by interfering with other pathways in the cell. If concentrated
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in a cell for long enough, DMOG can cause collagen processing to terminate from the
sustained inhibition of PHD2 61. This side effect is not exclusive to DMOG but has been
studied extensively with this small molecule.
1.2.3.3 Tilorone
A novel activator of the HIF-1α pathway, called tilorone, has been identified
for use in inhibition of PHD2 and stimulation of VEGF

82.

This novel compound has

not been used in many studies but has shown great potential in becoming a
therapeutic agent. A study by Ratan at el. showed that tilorone can induce VEGF
expression using a concentration 10 times less than that of desferrioxamine (10μM
vs. 100μM), a commonly used PHD2 inhibitor 85. Tilorone is an interesting compound
for use in HIF-1α activation because it does not successfully inhibit PHD2 but can still
cause an upregulation of VEGF and other angiogenic factors. It can be deduced that
tilorone activates HIF-1α independently of iron chelation, as many other compounds
are known to do.
1.3 SCAFFOLDS FOR LOCAL DELIVERY
1.3.1 Broad Review of Scaffolds
Tissue engineering, and the interchangeably used regenerative medicine, aims
to restore normal functionality to tissues through biomaterial scaffold-based
intervention, including cell transplants, engineered materials for small molecule
delivery, and tissue architecture methods 86,87. Scaffolds were identified as a means
to either replace tissue through decellularized/3D printed tissues and organs, or
regenerate it through delivery of cells, genes, drugs/small molecules, or growth
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factors 88–91. Early work in scaffold based tissue engineering can be traced back to Dr.
W. T. Green, M.D. and his attempt to regenerate cartilage with chondrocyte-seeded
bone spicules

92.

Since then, scaffolds have been optimized for many biomedical

applications and employ the use of natural and synthetic polymeric materials in
several different forms, including porous matrices, microspheres, nanofibers, and
hydrogels 93,94. Requirements for successful biomaterial scaffolds are: 1) the scaffold
must be biocompatible and should not induce an immune response; 2) the scaffold
should be biodegradable so that native tissue can replace the scaffold over time; 3)
the mechanical properties of the scaffold should closely match those of the native
tissue microenvironment for cell infiltration and longevity for complete remodeling;
and 4) the scaffold architecture should contain high porosity to allow sufficient cell
penetration and spreading, and vascularization

46.

One of the biggest challenges in

designing new scaffolds is simulating the mechanical and physicochemical properties
of the many different types of native tissues 95. Biomaterial scaffolds can provide the
framework for complete tissue regeneration, but advances in the technology are still
necessary to treat the ever-growing list of pathologies faced by researchers and
clinicians.
1.3.1.1 Polymeric Scaffolds
As mentioned above, polymeric materials are commonly used as biomaterial
scaffolds in tissue regeneration. Polymers contain large strings of monomers bound
together in a repeating unit, and can be naturally or synthetically derived

96.

The

choice of polymer depends on the application, as some materials possess properties
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that allow them to remain stable for long periods of time in biological environments,
i.e. nonbiodegradable synthetic polymers, while others benefit from being able to
degrade quickly, i.e. biodegradable synthetic and natural polymers

97.

Natural

polymers have strong bioactive properties that vary depending on the origin of the
material and include proteins and polysaccharides, agarose, collagen/gelatin,
hyaluronic acid, dextran, chitosan, and silk, among others

86,88,98,99.

Synthetic

polymers display strong mechanical properties and include poly(ethylene glycol)
(PEG), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(vinyl alcohol) (PVA),
poly(lactic-co-glycolic acid) (PLGA), and polycaprolactone (PCL), as commonly used
scaffold materials 86,88,100. Polymeric scaffolds of all types contain unique properties
like high porosity and surface area-to-volume ratio that make them suitable as drug
delivery systems and tissue engineering constructs

101.

For drug delivery systems,

microspheres and hydrogels have become popular due to their injectability and
ability to be shaped to fill the target site

102.

Herein, discuss both types of scaffolds

and their impact as drug delivery systems.
1.3.1.2 Microspheres
Polymeric microspheres were designed to be easily injectable drug, gene,
and/or protein delivery devices that can tailor release rate based on the material(s)
used, the type of cargo, and the pore and particle size of the microsphere

103.

Formation of microspheres are typically performed in emulsion, suspension, or
dispersion processes involving an oil-/organic-soluble or water-soluble polymers
dissolved in the appropriate solvent and dispersed in either water or oil, respectively,

28

to form oil-in-water (O/W) or water-in-oil (W/O) emulsions

104.

Polymerization by

emulsion involves dissolution of a water-soluble initiator with the desired monomer,
and combined with a surfactant to form micelles, where the polymerization of the
microspheres takes places 104,105. Microspheres formed in this manner are typically
uniform in size. Microsphere polymerization by suspension involves mixing of the
polymer and stabilizer in a water phase, with polymerization occurring from a
monomer phase-soluble initiator

104,106.

Microsphere sizing in suspension

polymerization is dependent on droplet size controlled by the rate of stirring.
Polymerization by dispersion involves the polymer, initiator, and stabilizer all
dissolved in oil/organic medium, with polymerization occurring within the monomer
droplets 104,107,108. Additionally, double emulsions have been used in the preparation
of microspheres by taking the (O/W) and (W/O) emulsions and stabilizing the
interfaces with either oil or water, respectively, to obtain porous microspheres
capable of controlled release of loaded drugs/cargo 104,109,110.
Microspheres can be fabricated from a single polymer type or in a copolymer
mix to customize the degradation profile. Combining monomers in various ratios
takes advantage of the individual properties of the polymers to be used in specific
situations 111. Cargo is typically entrapped within the microsphere and released upon
degradation of the material or in response to swelling, temperature, or pH change 112–
114.

Encapsulation efficiency of cargo is a product of emulsification temperature and

polymer phase concentration

112.

At high temperatures, encapsulation is driven by

rapid solvent evaporation and sphere hardening, while at low temperatures, is it
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driven by sphere hardening due to immiscibility of the polymer and water

115.

Changes in sphere and pore size also have an impact on the rate of release of loaded
cargo, with larger microspheres and smaller pores resulting in slower release profiles
116–118.

All microspheres tend to have an initial burst release from cargo trapped on

the surface, but controlled linear/constant release thereafter is achievable with the
combination of different monomer components, polymers of various molecular
weights, and spheres formed as core-shell systems, in addition to sphere and pore
size 119–122.
Microspheres for controlled delivery of drugs/cargo can be used in oral
administration, as well as an injected intravenously or during surgical treatment. Oral
administration of microspheres is typically used to deliver lower doses of potentially
harmful or insoluble drugs than what would be necessary for a therapeutically
effective dose from administering the drug alone

123,124.

Intravenous and injury site

delivery of microspheres allows for more local, targeted delivery of the encapsulated
drug. Intravenous delivery presents challenges with the blocking of blood vessels
from large or variable sized microspheres, and can be resolved by creating nano-sized
spheres from emulsion and dispersion polymerization methods 125–127. In most cases,
microspheres are best utilized to deliver drugs/cargo as a method of preventing rapid
cargo degradation and delivering more effective doses.
1.3.1.3 Hydrogels
Polymeric hydrophilic gels, or hydrogels, are characterized by the ability to
hold large quantities of water in the highly structured 3D network of polymer chains.
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Hydrophilic functional groups on the polymers used to create the network attract
water, but do not dissolve due to the crosslinking of monomers

128.

Hydrogels are

classified by the polymeric composition, the configuration, the type of crosslinking,
the physical appearance, and in some cases, the electrical charge of the network 128,129.
As with microspheres, hydrogels can be made from a single monomer type, or from a
combination of monomers that are covalently linked in an alternating configuration
(copolymer) or in an interpenetrating/semi-interpenetrating (IPN/semi-IPN)
network with two independently crosslinked/non-crosslinked polymers

128–130.

Crosslinking of polymers can occur physically as ionic, hydrophobic, or hydrogen
bond interactions, or chemically with an initiator that creates permanent covalent
bonds as network junctions 131,132. Chemical crosslinking agents can take the form of
small molecule spacers, polymer-polymer conjugation, photoinitiators, or can be
enzymatically driven, and are typically utilized to polymerize synthetic materials 133.
Natural polymers can be modified to take advantage of chemical crosslinking, but
most will form networks physically.
Hydrogels became popular in tissue engineering applications as constructs
made from natural polymers that could easily fill voids left by injury and promote
tissue regeneration based on the type of material used. Some materials used to
fabricate hydrogels also provide similar mechanical properties to native tissue and
provide better support for integration with the surrounding microenvironment.
Hydrogels that have too low or too high mechanical strength do not support optimal
tissue integration and can degrade either too quickly or too slowly, respectively, for
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the intended purpose

134.

Because of the various stimuli that can be used to swell

hydrogels (i.e. temperature, electrical/magnetic field, light, pressure, sound, pH
change, ionic presence, solvent composition), the range of potential applications
made hydrogels attractive for drug delivery purposes

135–138.

Delivery of drugs and

other cargo loaded into hydrogels can be controlled by any of the stimuli mentioned
above, as well as degradation of the gel matrix by biochemical means. Degradation of
hydrogels is determined by the type of material(s) used and directly impacts rate of
drug release. As with tissue integration, controlled drug release can be affected by the
mechanical strength of the hydrogel matrix, as a weak matrix will result in a faster,
burst-like release and a stronger matrix will yield a slow, drawn out release

139.

Optimization of polymer components tailors drug release profiles, making success
more likely for specific applications.
1.3.2 Drug Delivery Challenges and Macromolecular Prodrugs
If systemically delivered, drugs are typically degraded or cleared from the
body too quickly to be effective at non-toxic dosages, requiring supraphysiological or
repeat dosages that can trigger other systemic side effects 140. One solution to this is
using polymeric carriers, like hydrogels and microspheres, to regulate drug release.
This method, however, also presents challenges when choosing the appropriate
delivery method for incorporating hydrophilic and hydrophobic drugs, as hydrophilic
drugs tend to burst out and are difficult to keep from releasing too quickly, while
hydrophobic drugs are difficult to entrap

131,139,141.

In hydrogels, challenges in

regulating the rate of release can arise from the swollen, highly porous structure,
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although some hydrogels can be made non-porous

139,142.

Additionally, the

ineffectiveness in prolonging polar drug release and the struggle in loading non-polar
drugs can hinder hydrogels as viable options as extended release systems 139,143. To
overcome some of these challenges, techniques have been employed using drugloaded microspheres within hydrogel matrices to help with non-polar entrapment, as
well as hydrogel affinity systems that bind drugs to specific binding ligands, like
heparin, to control release 144–146. Further advances in drug delivery have led to the
creation of high molecular weight conjugates, or macromolecular prodrugs,
containing a large polymer backbone and one or more therapeutic drugs for targeted,
local delivery of the drug 147.
Conjugation of drugs to a polymeric macromolecule can help to alleviate some
of the issues faced by poor entrapment by creating linkages that are only severed by
specific actions from the body, like cell-mediated/enzyme-mediated degradation or
pH alterations

148,149.

In addition, macromolecular prodrugs help with solubility

issues of hydrophobic drugs that directly correlate to the problems with inefficient
loading in secondary delivery systems 150. Macromolecular prodrugs also provide a
layer of protection against premature degradation by sequestering the drug until
arrival at the target site due to the biocompatibility of the polymer backbone. The
relative size of these macromolecular prodrugs excludes them from possible
excretion but hinders them in penetrating the surrounding endothelium, reducing the
possibility of non-local uptake

151.

Using a biodegradable polymer as the

macromolecular backbone provides bioactive support that can drive the release of
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the conjugated therapeutic by cell-mediated actions, optimizing its pharmacokinetics
and localizing the uptake of the therapeutic by sheer proximity 152,153. On the other
hand, conjugation of a therapeutic to a macromolecular backbone can also aid in
systemic delivery by slowing down the rate of release while in circulation, prolonging
the effects of the released therapeutic 154. Both natural and synthetic polymers have
been used as the drug carrier, with polysaccharides (hyaluronic acid (HA), dextran),
poly(ethylene glycol) (PEG), and N-(2-hydroxypropyl) methacrylamide (HPMA)
among some of the polymers used in studies

155–158.

Macromolecular prodrugs are

utilized, and often praised, for the stealth-like properties associated with the neutralcharged backbone that sequesters the therapeutic until released by external means.
1.3.3 Hydrogel Compositions
The composition of hydrogels and the chosen concentrations of the polymers
used are based on the desired effects for a given application and are optimized
accordingly. Properties of the hydrogel should try to match those of the native tissue
in the surrounding microenvironment to better support cell integration with the
surface and bulk of the material. This will, in turn, provide a more suitable system for
delivery of embedded therapeutics. Hydrogels, as mentioned previously, are
hydrophilic gels made from natural and/or synthetic polymers that are polymerized
by various methods, including physical and chemical crosslinking, that can be
dependent on polymer concentration. At low polymer concentrations in solution, no
crosslinking or entanglement occurs, displaying Newtonian behavior unless a
crosslinking agent is added. Physical crosslinking can occur spontaneously, by

34

protein or ion interaction, or with changes in temperature or pH, while chemical
crosslinking can occur by addition/condensation reactions, ultraviolet (UV)
photopolymerization,

or

enzymatically

driven

reactions

159–165.

Polymer

concentration has a direct impact on the strength, swelling, and degradation
properties of the resulting hydrogel, as higher concentrations can yield higher
strength, reduced swelling, and slower degradation 166.
1.3.3.1 Natural Versus Synthetic Hydrogels
Naturally derived polymers are innately biocompatible, biodegradable, and
possess bioactive properties, like surface RGD peptides for cell adhesion

167.

Of the

natural polymers used to create to hydrogels, there are four main categories,
including proteins, polysaccharides, protein/polysaccharide hybrids, and DNA 168–171.
These polymers are useful for cell-hydrogel interactions to support cell adhesion and
migration, as well as degradation, particularly for drug delivery. Natural polymers,
however, do not possess strong mechanical properties and have the potential to incite
an immune reaction upon implantation 172. Synthetic polymers are innately stronger
due to the covalent crosslinking needed to form the hydrogel matrix, are easily
functionalized, and can be synthesized in large quantities. These polymers can be split
into three types, including biodegradable, nonbiodegradable, and bioactive

173–175.

Unlike natural polymers, synthetic polymers are passive systems and do not possess
strong bioactive properties, if any, and must be supplemented with other materials in
order to gain those abilities, as in hybrid systems 176.
1.3.3.2 Hybrid Hydrogels

35

Hybrid hydrogels utilize natural and synthetic polymers to take advantage of
the individual strengths associated with each. Natural polymers contribute bioactive
properties via tertiary structures to influence biological responses and cell-mediated
remodeling, while synthetic polymers contribute superior mechanical properties
from covalent crosslinking of functional groups and a reduced chance of an
immunogenic response

177,178.

Hybrid hydrogels containing covalently crosslinked

synthetic polymers and entrapped natural polymers provide unique pockets of phase
separated natural polymer that can increase support for cell migration and spreading
179.

Some natural polymers, however, can also be functionalized to be covalently

crosslinked with compatible synthetic polymers

180,181.

This method results in a

natural and synthetic copolymer system that does not display much phase separation
but creates a highly structured, tunable, bioactive system capable of optimizing
mechanical properties, chemical compositions, and cell signaling/extracellular
matrix mimicry.
1.3.3.3 Combinatorial Prodrug Hydrogels
As mentioned earlier, macromolecular prodrugs are drug conjugates
synthesized by linking a macromolecule backbone to a therapeutic drug that
improves the pharmacokinetics and targeting capabilities of the drug. In many cases,
the macromolecule is a polymer that is also readily used in hydrogel scaffold
formulations, making some macromolecular prodrugs suitable candidates for
incorporation into hydrogel drug delivery systems 182–184. Previous work by Bae et.
al. has shown the effectiveness of crosslinking HA-based macromolecular prodrugs
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into PEG-based hydrogels and the added protection from proteolytic degradation that
the hydrogel provides

185.

Some linkages binding the macromolecule to the drug,

often ester bonds, are designed to be severed by cell-mediated actions, while others
are severed in response to changes in the local microenvironment, like pH shifts
186,187.

Since the macromolecular prodrug is entrapped within the hydrogel matrix,

breaking of these bonds requires cell invasion into the hydrogel matrix or requires
bulk degradation to release the therapeutic from within the matrix. In this case, rate
of drug release is dependent on the rate of cell migration but can provide sustained
release if the hydrogel components support cellular actions. Other hydrogel systems,
like those formulated by Ashley et. al., utilize β-eliminative linkers with highly porous
matrices to promote diffusion, while the matrix itself degrades slowly

188.

Incorporating a macromolecular prodrug into a hybrid hydrogel allows for better
cell-matrix interactions that can help control the rate of drug release, while providing
two layers of protection against any premature degradation or clearance

189,190.

Despite this, macromolecular prodrug-loaded hybrid hydrogels are not the final
solution to overcoming issues with drug delivery, as hydrogel matrices still need
optimization to mimic the extracellular matrix more closely for seamless integration
with native tissue and prevent any adverse reactions. Additionally, rate of drug
release, although highly tunable, may be inconsistent if the system is not well
integrated with the local microenvironment., preventing a sustained therapeutic dose
from being delivered.
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CHAPTER TWO
SPECIFIC AIMS AND SIGNIFICANCE

2.1 AIM I: Synthesize and characterize HA-NOG conjugate and perform
bioactivity analyses in vitro
SubAim 1: Synthesize and characterize HA-NOG conjugate
SubAim 2: Measure release of NOG from HA-NOG conjugate with/without enzymes
SubAim 3: Determine bioactivity of released NOG from HA-NOG conjugate by
activation of HIF-1α pathway
2.1.1 Rationale
Therapeutic angiogenesis aims to stimulate the formation of new
microvasculature that alleviates hypoxia, reduces tissue morbidity and improves
wound healing

9,36,191.

In these studies, we sought to develop a biomaterial-based

system for local, sustained release of a bioactive small molecule capable of activating
the HIF-1 signaling pathway. Under normoxia, PHD2 and FIH enzymes modify HIF-1α
with hydroxyl groups that provide sites for ubiquitin ligation, targeting it for
proteasomal degradation or interference with its DNA-binding ability by blocking its
p300 binding site 56,57,192. Under hypoxia, the activity of these O2-dependent enzymes
is inhibited, allowing HIF-1α to translocate to the nucleus and bind with HIF-β subunit
56,57,192.

The HIF-1 transcription factor then initiates the binding of other co-factors to

begin transcribing pro-angiogenic target genes, including VEGF, bFGF, glucose
transporter 1 (GLUT1), platelet-derived growth factor (PDGF), EPO, and placenta
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growth factor (PLGF), among many others 11,193–195. In addition to O2, both PHD2 and
FIH enzymes also require iron and 2-oxoglutarate (2-OG) as co-factors. Therefore,
iron chelators and competitive analogues of 2-OG have been widely investigated for
their ability to stabilize HIF-1α. N-oxalylglycine (NOG), a 2-OG analogue, has been
studied for its effectiveness in promoting angiogenesis by inhibiting the 2-OGdependent complexes, PHD2 and FIH 11,196–198. NOG is the precursor of DMOG, a 2-OG
analogue, but was designed to inhibit PHDs and be more soluble in water than DMOG
197,199,200.

Studies using NOG, however, show that it is a stronger inhibitor of FIH, but

still effectively inhibits PHDs and activates the angiogenic pathway

197,201.

NOG has

been identified as a more effective stabilizer of HIF-1α than most other proangiogenic small molecules studied for therapeutic use.
As noted earlier, efficient delivery is a substantial challenge in the therapeutic
use of small molecules

36,202,203.

Based on previous work with HA-DXM, here we

conjugated NOG to HA to create a macromolecular prodrug that can be incorporated
into a hydrogel. In this manner, NOG is sequestered in the hydrogel network until
released by cellular enzymes, allowing local, sustained delivery. In SubAim 1, we
began to characterize a newly synthesized HA-NOG conjugate by verifying the
chemical structure and degree of substitution. In SubAim 2, we tested the release
kinetics of NOG from HA-NOG in the presence of degradative enzymes to confirm that
release is enzymatically driven and that the conjugate could remain stable when
those enzymes are not present. In SubAim 3, we evaluated the cellular response to
HA-NOG exposure to determine if accumulation of HIF-1α occurred with subsequent
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increase in angiogenic target gene expression. Additionally, SubAim 3 assessed the
impact of HA-NOG on metabolic pathways to understand the potential toxicity of HANOG on cellular function. The final studies for this Aim used an endothelial cell
tubulogenesis assay to confirm that cells treated with HA-NOG secrete bioactive, proangiogenic factors.
2.2 AIM II: Evaluate release kinetics and bioactivity of NOG from PEGdA/HANOG semi-IPNs
SubAim 1: Measure release of NOG from PEGdA/HA-NOG with/without enzymes
SubAim 2: Confirm bioactivity of released NOG from PEGdA/HA-NOG at various time
points
2.2.1 Rationale
Hydrogels have been extensively studied as delivery carriers for therapeutics
as they provide a convenient and minimally invasive method of delivering cellular
transplants and biomacromolecules

83,93,204,205.

PEG is a common synthetic polymer

used in the preparation of hydrogel drug delivery systems because of its
hydrophilicity, stability, and biocompatibility 97,189,206,207. In our lab, we synthesized
hydrolytically degradable, crosslinkable PEG-based macromers with variable alkyl
chain length spacers [PEG-bis-acryloyloxy acetate (AA), PEG-bis-acryloyloxy
propanoate, and PEG-bis-acryloyloxy butyrate (AB)] and observed that degradation
rates from days to months could be attained by varying macromer composition and
concentration 179,208,209. We observed that combining these modified PEG diacrylate
(PEGdA) derivatives with HA resulted in hybrid semi-IPN hydrogels that supported
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hyaluronidase-dependent cell migration and proliferation

179,185,208.

Addition of HA

into PEGdA hydrogels allows cells to interact with the gel matrix and initiate
degradation of the hydrogel

210–212.

Through this interaction, HA-based drug

conjugates were reasoned to be strong candidates for local, sustained release of
bioactive small molecules based on the idea that the drug would be sequestered until
cell-derived, enzyme-mediated release

183,185,213,214.

Previous work in our lab

demonstrated successful implementation of this concept through cell-mediated
release of dexamethasone (DX) from PEG-bis-AP/HA-DXM hydrogels for osteogenic
differentiation of encapsulated mesenchymal stem cells

185.

In another study, we

demonstrated that release of dexamethasone from PEG-bis-AA/HA-DXM reduced the
inflammatory response after traumatic brain injury (TBI) in a rat controlled cortical
impact TBI model 215. In these studies, different derivatives of PEGdA were utilized
based on the desired DX release kinetics. For the pro-osteogenic effects, PEG-bis-AP
was utilized for slower/prolonged release of dexamethasone, as it can take 2+ weeks
for the osteogenic program to be fully operational

179,185,209.

For the acute anti-

inflammatory effects of DX for TBI, PEG-bis-AA was used because of its faster
degradability/release kinetics179,209.
In these studies, we aimed to achieve sustained, local release of bioactive NOG
from a hybrid hydrogel to promote angiogenesis. Sufficient microvessel formation for
treatment of ischemic injury is a long-term process that requires upfront activation
of the angiogenic pathway 216–218. In previous studies, PEG-bis-AA was shown to be a
quick degrading hydrogel to deliver loaded drugs quickly within 1 week, while PEG-
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bis-AP demonstrated complete mass loss over 3 weeks, making it a viable option for
longer-term drug release

179,208,209.

Combining the early and prolonged release

profiles of the PEGdA derivatives in a bilayer hybrid hydrogel covers the initial need
for upfront angiogenic activation and supplements it with sustained drug release. In
SubAim 1, we prepared hybrid monolayer (PEG-bis-AA or PEG-bis-AP) and bilayer
(PEG-bis-AA and PEG-bis-AP) hydrogels with HA, HA + free NOG, and HA-NOG and
tested the release kinetics in the presence and absence of hydrolytic enzymes (Table
1). Additionally, in SubAim 2, we confirmed the bioactivity of released NOG based
upon its ability to activate angiogenic gene expression as observed in completed
studies for Aim 1.
2.3 AIM III: Evaluate alternative purification method for GelMA by acetone
precipitation
SubAim 1: Synthesize and characterize structure of GelMA precipitated in acetone
SubAim 2: Compare mechanical and bioactive properties against dialyzed GelMA
2.3.1 Rationale
As of today, the current methods for synthesizing GelMA involve a lengthy
dialysis and lyophilization process that can significantly slow down or hinder
research groups wanting to evaluate various experimental formulations

219.

At the

academic level, this can be a major issue, but may not translate as being as hindering
at the industrial level. The objective of this study was to present an alternative
method for purifying GelMA that drastically reduces the overall synthesis and
recovery time from ~8-10 days to 2-3 days. The structural, mechanical, and bioactive
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properties were assessed for acetone precipitated GelMA samples and compared
against samples synthesized by the traditional dialysis method. The goal of these
assessments was to evaluate the differences, if any, in the products of the two GelMA
purification methods and determine if acetone precipitation is a viable alternative
method.
2.4 AIM IV: Synthesize and characterize PEGdA/GelMA/GMHA hybrid hydrogel
and perform bioactivity analyses in vitro
SubAim 1: Synthesize and characterize structure of hybrid hydrogel
SubAim 2: Determine mechanical properties of various hybrid hydrogel formulations
SubAim 3: Determine bioactivity of hybrid hydrogel formulations
2.4.1 Rationale
Hydrogels have been extensively studied as scaffolds for therapeutic
purposes. With their ability to be readily modified, they provide a convenient and
minimally invasive method of delivering therapeutic agents to target sites. Many
hydrogel formulations have been optimized to mimic the viscoelastic properties of
soft tissues to better suit the environment for implantation

220–223.

Using naturally

derived polymers (i.e. gelatin, hyaluronic acid) as hydrogels can add support for
cellular processes, but do not provide the necessary mechanical properties for
stability within a physiological environment 224–227. On the other hand, using synthetic
polymers (i.e. PEG) can support the physiological environment by adding superior
mechanical properties, but do not provide the bioactive support that natural
polymers provide

95,204,228.

Recent studies have utilized the use of both natural and
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synthetic polymers to form tunable hybrid hydrogel systems

97,176,229,230.

The

combination of polymers is more mechanically and biologically suitable than either
polymer type when used alone. This provides greater support for cell adhesion and
migration throughout the hydrogel. Natural and synthetic polymers can be modified
by adding acrylate and methacrylate groups to the native chains 97,205,212. Modifying
polymers in this manner allows highly structured and stable semi-IPNs to form by
Michael addition click reactions.
Previous work has shown that differences in polymer concentrations can
cause varying degrees of phase separation when polymerized

179.

By phase

separating, there is an uneven distribution of polymers causing inhomogeneous
material properties within the hydrogel. Swell testing of hybrid hydrogels
determined degree of gelation for different polymer compositions and how varying
concentrations impacts swelling. Determining the turbidity of various hydrogel
compositions ruled out any combinations that may be too phase separated. Changes
in polymer concentrations have been shown to alter the mechanical properties of the
hydrogel

179,208,209.

Compression testing of cylindrical hydrogels determined which

hydrogel compositions were mechanically suitable for interaction with cells and
tissues. Cellular interactions with the hydrogel are also controlled by the stability and
protein content within the scaffold. We tested cell adhesion to the surface of each
hydrogel, as well as tested the ability of cells to invade and migrate within the matrix.
The ultimate goal was to have a hybrid hydrogel system that displayed superior
bioactive properties to that of PEGdA/HA semi-IPNs, as previously studied 179.
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2.5 SIGNIFICANCE/INNOVATION
Currently, the primary approach for small molecule drug delivery is
dissolution in a compatible solvent and systemic administration

202,203.

Most small

molecule drugs are quickly cleared from circulation and have short half-lives

36,231.

Therefore, novel delivery systems for small molecule drugs are necessary to achieve
therapeutic concentrations in the target tissue, while minimizing adverse side effects.
Various biomaterial-based drug delivery systems including polymeric microspheres
and hydrogels have been used for entrapment and controlled release of small
molecules in a target area

232–234.

However, both approaches have limitations that

need to be respected. Microspheres are commonly fabricated from relatively
hydrophobic, degradable polyesters such as poly(lactide-co-glycolide). Although
successful in some applications, challenges include burst release of poorly entrapped
drug, inefficient loading of hydrophilic drugs and release kinetics that are controlled
by polymer chemistry with little responsiveness to the biological environment 235,236.
Hydrogels face important limitations like the difficulty to include non-polar small
molecules within their matrix and the inability to keep polar small molecules from
releasing too quickly

139,141,143.

To overcome these challenges, we utilized a

macromolecular prodrug approach in which the hydrophilic small molecule NOG was
covalently conjugated to the macromolecule, HA. HA has been a prominent
macromolecule used in successfully conjugating small molecules, including paclitaxel,
curcumin, and dexamethasone for use in anti-cancer/anti-tumor, anti-inflammatory,
and osteoinductive treatments

183,185,213,214.
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Further, we incorporated this

macromolecular prodrug within a bilayer gel with two layers having different
degradation profiles. This research is innovative, in our opinion, because of the
unique combination of macromolecular prodrug and degradable hydrogel that
prevents early clearance, enhances targeted delivery, and provides a sustained dose
of NOG in the local tissue.
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CHAPTER THREE
AIM I: SYNTHESIS AND CHARACTERIZATION OF A HYALURONIC ACID-NOXALYLGCLYCINE MACROMOLECULAR PRODRUG CONJUGATE

3.1 INTRODUCTION
Therapeutic angiogenesis seeks to activate and augment the body’s intrinsic
mechanisms for creating new microvasculature in order to alleviate tissue ischemia
resulting from vascular pathology and traumatic injury

9,36,237.

Hypoxia-inducible

factor-1α (HIF-1α), the heterodimeric master transcription factor of oxygen-sensing
pathways is the key to this process 11,238. HIF-1α stability and activity are regulated
by enzymes that require oxygen (O2), iron (Fe+2), and 2-oxoglutarate (2-OG). In a
normoxic environment, HIF-1α is modified with a hydroxyl group at Pro402/564 by
prolyl hydroxylase domain enzymes (PHDs), promoting binding of the von Hippel
Lindau (VHL) ubiquitin ligase complex and targeting for proteasomal degradation
82,239–241.

In addition, Factor Inhibiting HIF (FIH) can modify HIF-1α with a hydroxyl

group at Asn803, blocking its CREB-binding protein (CBP)/p300 nuclear co-activator
binding site to prevent transcription 242,243. In a hypoxic environment, PHDs and FIH
are inactivated by lack of O2, allowing HIF-1α to translocate to the nucleus, complex
with HIF-1β, bind to hypoxia response elements (HRE), and initiate transcription of a
wide range of target genes. Among these are numerous pro-angiogenic factors,
including vascular endothelial growth factor (VEGF), erythropoietin (EPO), basic
fibroblast growth factor (bFGF), and platelet-derived growth factor (PDGF)
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21,244.

These growth factors stimulate the formation of new microvessels to alleviate
ischemia and support tissue repair.
Delivery of exogenous, pro-angiogenic growth factors is the most widely
studied approach to activating therapeutic angiogenesis, particularly VEGF that is
widely recognized for its ability to increase vascular permeability and stimulate
endothelial cell proliferation, migration, and tubulogenesis 195,245. VEGF injection has
been shown to initiate angiogenesis in numerous preclinical models, however, the
newly formed microvessels are often leaky, immature, or unstable and its efficacy in
human clinical trials has been limited

246,247.

One approach to overcome these

challenges is the development of improved, biomaterial-based delivery systems that
provide spatiotemporal control of VEGF release or sequential release of VEGF and
other angiogenic factors such as platelet-derived growth factor (PDGF) that recruits
mural cells to stabilize newly formed microvessels (recently reviewed in 248,249).
Another approach is directly targeting HIF-1α to more broadly activate the
angiogenic pathway. Gene therapy using vectors encoding constitutively active forms
of HIF-1α have been shown to promote angiogenesis in a variety of tissues

250.

However, clinical translation is hindered by limited control over expression levels
and possible detrimental side effects of prolonged, high level expression of VEGF and
other HIF-1α targets.

50

Consequently, small molecule stabilization of HIF-1α is

becoming a promising option for targeting the angiogenic pathway. Iron chelators, 2OG competitive mimics, phenolic compounds, and tricarboxylic acid cycle
intermediates have all been shown to inhibit PHD and FIH with varying selectivity,
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inducing a pseudo-hypoxic response including HIF-1α stabilization and subsequent
activation of pro-angiogenic gene expression

54,251,252.

The most widely studied

compounds include the iron chelator, DFO, and the 2-OG mimic N-oxalylglycine (NOG)
and its derivative dimethyloxalylglycine (DMOG) that have been shown to increase
vascularization and improve healing in diabetic ulcers, bone fractures, and traumatic
brain injury

253–257.

Relative to recombinant growth factors, small molecule

therapeutics are advantageous due to their stability, cost effectiveness, and limited
immunogenicity. However, delivery still presents some challenges as they are
typically distributed systemically and cleared from the body too quickly 258,259.
Currently, the primary approach for small molecule delivery is dissolution in
a compatible solvent and systemic administration

260,261.

Incorporation and release

from biomaterial-based delivery systems seeks to achieve therapeutic concentrations
in the target tissue, while minimizing adverse side effects. One approach to improve
the solubility and biodistribution of small molecules is their conjugation to polymers
to create macromolecular prodrugs. Hyaluronic acid (HA), a naturally-occurring
glycosaminoglycan (GAG), has been used as a macromolecular backbone for
conjugating a wide range of small molecules including taxol, dexamethasone (DX),
and curcumin for use in anti-cancer/anti-tumor, anti-inflammatory, and wound
healing applications

183,214,262,263.

Recently, we described semi-interpenetrating

polymer network hydrogels composed of photocrosslinked polyethylene glycol
diacrylate and DX-conjugated HA as matrices for tissue repair via local drug delivery.
These networks have been shown to provide cell-mediated, sustained DX release;
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support in vitro osteogenesis of encapsulated human mesenchymal stem cells; and
reduce secondary injury and improve functional recovery in a rodent traumatic brain
injury model

185,215.

The objective of this study was to develop a macromolecular

prodrug for therapeutic angiogenesis. We describe the synthesis and characterization
of N-oxalylglycine-conjugated HA (HA-NOG) and show its ability to stabilize HIF-1α,
increase transcription of HIF-1α targets, and promote endothelial cell tubulogenesis.
3.2 MATERIALS AND METHODS
3.2.1 Materials
Hyaluronic acid (HA, sodium salt, MW 1.5 MDa) was purchased from LifeCore
Biomedical (Chaska, MN). Carbonyldiimidazole (CDI), triethylamine (TEA),
anhydrous dimethylsulfoxide (DMSO), 4-(dimethylamino)benzaldehyde (DMAB), 2propanol, hydrochloric acid (HCl), sodium hydroxide (NaOH), citric acid
monohydrate, anhydrous sodium acetate, glacial acetic acid, Chloramine-T, and
ascorbic acid 2-phosphate (AA2P) were purchased from Sigma-Aldrich (St. Louis,
MO). Tetrabutyl ammonium bromide (TBA-Br) and Dowex 50WX8 200−400(H) were
purchased from Alfa Aesar (Ward Hill, MA). N-oxalylglycine (NOG) was purchased
from Cayman Chemical (Ann Arbor, MI). Normal human dermal fibroblasts (NHDF),
human umbilical vein endothelial cells (HUVECs), and endothelial cell growth
medium (EGM-2) were purchased from Lonza (Walkersville, MD). Dulbecco’s
modified Eagle medium (DMEM), growth factor reduced Matrigel, and bovine growth
serum (BGS) were purchased from Corning Life Sciences (Tewksbury, MA). Medium
200PRF was purchased from Thermo Fisher (Waltham, MA).
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3.2.2 Synthesis and Characterization
3.2.2.1 HA-TBA Synthesis
Dowex ion-exchange resin (3.0g) was mixed with excess TBA-Br (5.0g) for 1
hour, washed, and then added to sodium hyaluronate (250mg) dissolved in 50mL of
distilled water. After 3 hours, the mixture was centrifuged (3 min at 4000 rpm), the
supernatant was collected and freeze-dried to obtain HA-tetrabutylammonium salt
(HA-TBA).
3.2.2.2 HA-NOG Conjugate
N-oxalylglycine-conjugated hyaluronic acid (HA-NOG) was prepared in two
steps: First, the terminal carboxyl group of N-oxalylglycine (NOG) was activated with
1,1’-carbonyldiimidazole (CDI). The reaction was performed at two molar ratios of
NOG to the HA disaccharide (0.85:1 and 1.7:1), corresponding to 10 and 20 mg NOG,
respectively. NOG (10mg, 0.068mmol or 20mg, 0.136mmol) was dissolved in 2 ml
DMSO and TEA (45.48μL, 0.3263mmol) added. CDI (48.5mg, 0.2991mmol) was
dissolved in 2 ml DMSO, added dropwise to the NOG/TEA solution, and stirred for 2
hours. In the second step, the activated NOG was conjugated to the hydroxyl groups
of HA-TBA in the presence of TEA to obtain HA-NOG. HA-TBA (50mg, 0.0804mmol)
was dissolved in 20mL DMSO and stirred for 24 hours. The activated NOG/CDI
solution was slowly added to the dissolved HA-TBA and stirred for 48 hours in the
dark. Sodium chloride (2.0M) was added to the reactant solution at 10% volume ratio
for the exchange of TBA+ by Na+ ions. The solution was then purified by dialysis
against ultrapure MilliQ water in 12-14kDa MWCO tubing for 72 hours, filtered
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(0.45μm cellulose acetate filter), and recovered by lyophilization. The structure of
HA-NOG was analyzed by ATR-FTIR using a Thermo-SpectraTech Foundation Series
Endurance Diamond ATR (Thermo-Nicolet Magna 550) and compared to native HA.
To measure the degree of substitution (DS), HA-NOG was hydrolyzed using 0.1N
sodium hydroxide (NaOH) at 60°C for 1 hour, the pH neutralized with 0.1N
hydrochloric acid (HCl) and diluted with 1x PBS to a final concentration of 2 mg/mL.
The concentration of NOG was measured by UV absorbance at 220nm using a
NanoDrop 2000c UV-Vis Spectrophotometer (Thermo Fisher) and standard curve of
NOG serially diluted in a solution of 2 mg/mL alkaline hydrolyzed HA. The DS of
conjugated NOG was calculated as mg NOG/100mg HA-NOG.
3.2.2.3 Enzymatic Release of NOG from HA-NOG Conjugate
NOG release from soluble HA-NOG was evaluated in physiological buffer alone
and with the addition of hydrolytic enzymes such as hyaluronidase (Hase) and
esterase (Ease). HA-NOG and was incubated in 0.1M PBS (pH 7.4) solution, 0.1M PBS
containing Ease (5 U/mL), and 0.1M PBS containing Ease and Hase (5 U/mL each) at
37 °C. Samples (100μL) of each solution were removed each day for 7 days and stored
at −20 °C until analysis. Samples (20μL) were treated with methanol (80μL),
centrifuged, and filtered using a 0.2μm syringe filter. The concentration of released
NOG was measured by UV spectrophotometry as described above.
3.2.3 Evaluation of Angiogenic Bioactivity
3.2.3.1 Cell Culture

52

Cell culture for in vitro analysis was performed using NHDF or HUVECs. NHDF
cell culture medium consisted of DMEM/F-12 50/50 with L-glutamine (Corning)
supplemented with BGS and penicillin / streptomycin. HUVECs were cultured in EGM
supplemented with an EGM-2 BulletKit.
3.2.3.2 HIF-1α Stabilization
NHDF cells were seeded at 20,000 cells/well in 96-well plates and cultured at
37°C for 24 hours. The medium was exchanged and the cells were cultured under the
following experimental conditions: untreated, HA (72μM), HA-NOG (72μM,
equivalent to 10μM NOG based on DS calculations), NOG (10μM), cobalt chloride
(CoCl2, 300μM), and hypoxia (1% O2). After 6 hours, the plates were immediately put
on ice and fixed with methanol. Methanol was removed and staining media (95% 1x
PBS w/o Ca+2/Mg+2, 5% BGS, 0.1% NaN3) was added for blocking. HIF-1α primary
antibody (Novus Biologicals, H1alpha67) at 1:100 dilution in staining media was
added to the wells for 60 minutes. Wells were rinsed with staining media and
incubated with goat anti-mouse IgG DyLight 488 secondary (Abcam, 1:220 dilution in
staining medium) for 60 minutes in the dark. Wells were rinsed three times and DAPI
dihydrochloride (Invitrogen, 300nM) counterstain was applied for 5 minutes. The
wells were rinsed and imaged using an inverted fluorescence microscope (Zeiss
Axiovert 200).
3.2.3.3 Expression of HIF-1α Target Genes
Using NHDF, two studies were performed to test the ability of HA-NOG to
increase mRNA expression of HIF-1 target genes and the dose-dependence of this
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response. NHDFs were seeded (300,000 cells/well) in 6-well plates, cultured at 37°C
for 24 hours, and then the medium exchanged. In the first study, cells were cultured
under the following experimental conditions for 6 hours: untreated, HA (72μM), HANOG (72μM), NOG (10μM), and hypoxia (1% O2). In the second study, cells were
cultured 6 hours with varying concentrations of HA-NOG (7.2μM, 18μM, 36μM, and
72μM) and untreated control. Cells were lysed with TRIzol Reagent (Ambion) and the
aqueous phase transferred to RNeasy columns (Qiagen) for purification. Isolated RNA
was treated with DNase I using TURBO DNA-free kit (Invitrogen). A Take 3 microplate
reader (Biotek Instruments) was used to determine quantity and quality of isolated
RNA by UV absorbance. Purified RNA (1μg) was reverse transcribed with a High
Capacity cDNA RT kit (Applied Biosystems) and real-time qRT-PCR was performed
using PowerUp SYBR Green Master Mix (AB) with custom sense and anti-sense
primers (5μM, Table 3.1) for vascular endothelial growth factor (VEGF), glucose
transporter 1 (GLUT1), prolyl hydroxylase domain 2 (PHD2), and β-2 microglobulin
(β2MG) as an internal standard, using a Rotor-Gene Q thermal cycler (Qiagen).
Relative mRNA expression levels were quantified by the 2-ΔΔCt method with results
expressed as relative fold changes 264.
Table 3.1: Primer sequences used in real-time qRT-PCR
Gene

Forward Primer (5’-3’)

Reverse Primer (5’-3’)

GeneBank no.

Product size
(bp)

VEGF
PHD2

CCTTGCCTTGCTGCTCTACC
TGTTATCCGGGCAATGGAAC

ACCAGGGTCTCGATTGGATG
AAACTGGGCTTTGCCTTCTG

NM_001171630
NM_022051

144
156

GLUT1

ACTCTTCAGCCAGGGTCCAC

CGTAGGGACCACACAGTTGC

NM_006516

119

β2MG

TGTGCTCGCGCTACTCTCTC

CGGATGGATGAAACCCAGAC

NM_004048

137

*All primer sequences were designed based on gene sequence obtained from the respective GeneBank numbers
using Primer-Blast (http://www.ncbi.nih.gov/tools/primer-blast/).
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3.2.3.4 Tubulogenesis Analysis
NHDF were seeded (300,000 cells/well) in 6-well plates with low-serum
DMEM (1% serum) and incubated at 37°C for 24 hours. Medium was exchanged and
cells were cultured under the following experimental conditions for 24 hours:
untreated, HA (72μM), HA-NOG (72μM), NOG (10μM), hypoxia (1% O2), and CoCl2
(300μM). Conditioned cell culture medium (5mL) was harvested and stored at -80°C
for later use. HUVECs were seeded (20,000 cells/well) in a growth factor-reduced
Matrigel-coated 96-well plate with low-serum Medium 200PRF (1% serum) (100μL).
After 3 hours for attachment, medium was replaced with the conditioned media
(100μL) obtained from NHDF cultured under various experimental conditions and
cells were cultured for 6 hours to allow in vitro tubulogenesis. HUVECs were fixed and
imaged using a light microscope, and total tube length was measured with ImageJ.
3.2.4 Cytotoxicity
3.2.4.1 Metabolic Activity Analysis
NHDF were seeded (50,000 cells/well) in 24-well plates and cultured for 24
hours, and then the medium was exchanged and cells were cultured under the
following experimental conditions for 5 days: untreated, HA (72μM), HA-NOG
(72μM), and NOG (10μM). AlamarBlue reagent (Thermo Fisher) was added in a
volume equal to 1/10th the volume of the cell culture media in each well. After 12
hours, fluorescence readings (555nm excitation, 590nm emission) were taken using
a Biotek Synergy 4 plate reader.
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3.2.4.2 Hydroxyproline/Collagen Assay
Porous Tecoflex polyurethane sponges were fabricated as previously
described

265.

NHDF were seeded (2.4x106 cells/scaffold) on fibronectin-coated

Tecoflex sponges, cultured 24 hours, and then the medium was exchanged and the
materials cultured under the following experimental conditions: untreated, HA, HANOG (72μM), and NOG (10μM). AA2P (1mM) was added every 3 days with the
changing of the cell culture media to ensure proper collagen formation. After 14 days,
the sponges were rinsed with 1x PBS and stored at -80°C for 24 hours. Before use,
sponges were subjected to repeated freeze/thaw cycles (-80°C/37°C) to lyse the cells.
Samples were then transferred to glass test tubes and 1mL of 12N HCl added to each.
Samples were hydrolyzed at 120°C for 3 hours, cooled for 20 minutes, transferred to
new microcentrifuge tubes, and centrifuged at 10,000rpm for 3 minutes. 20μL of each
supernatant were transferred to a 96-well plate and dried in a vacuum oven for 12
hours. Hydroxyproline content was assayed as previously described

266.

Briefly,

samples were mixed with 100μL of Chloramine-T solution (0.05M Chloramine T in
74% v/v H2O, 26% v/v 2-propanol, 0.629M NaOH, 0.140M citric acid monohydrate,
0.453M anhydrous sodium acetate, and 0.112M glacial acetic acid) at room
temperature for 20 minutes and then 100μL of Ehrlich’s solution (1M DMAB in 30%
v/v HCl and 70% v/v 2-propanol) was added and heated at 65°C for 20 minutes. The
96-well plate was immediately put on ice for 5-10 minutes to quench the reaction. A
standard curve was prepared by serial dilution from a 400 μg/mL hydroxyproline
sample. Absorbance readings were taken at 558nm using a Biotek Synergy 4 plate
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reader. Hydroxyproline content was then normalized to the amount of DNA, as
previously described

267,268.

A standard curve of DNA was made from freeze/thaw

lysed cell samples of specific densities (100k, 250k, 500k, 1M, and 2M cells), alongside
experimental samples in 5mL tubes. Lysed samples were treated with cold 10mM
EDTA, pH 12.3 solubilization buffer (1.4mL), incubated for 20 minutes at 37°C,
neutralized with 1M potassium phosphate (0.1mL), and placed on ice. Hoechst 33258
DNA-binding dye (200 ng/mL, 1.5ml) was added to samples, samples (200μL) were
transferred to a 96-well plate, and fluorescence was measured at 350nm excitation,
455nm emission using a Biotek Synergy 4 plate reader.
3.2.5 Statistical Analysis
Statistical comparisons were performed using one-way analysis of variance
(ANOVA). P-values less than 0.05 were considered significant. Data are expressed as
mean +/- standard deviation with significant differences marked as * (p < 0.05).
3.3 RESULTS
3.3.1 Synthesis and Characterization of HA-NOG
HA-NOG was synthesized by CDI-mediated esterification between the NOG
carboxylic acid group and HA hydroxyl group (Figure 1A).
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Figure 3.1. Structure of HA-NOG characterized by ATR-FTIR. A) Predicted structure
and B) FTIR spectrum of HA-NOG showing ester carbonyl peak at 1727cm-1 along
with peaks originating from HA.

Using ATR-FTIR, the structure of HA-NOG (Figure 3.1A) was verified and
compared with native HA (Figure 3.1B). Both spectra showed the broad O-H stretch
for HA from 2800-3600cm-1 and C=O stretch for carboxylic groups at 1609cm-1. For
HA-NOG, the IR spectrum included an ester carbonyl peak at 1727cm-1. We first
performed the synthesis at 0.85:1 NOG/HA molar ratio), which resulted in a DS of
2.52%. When the amount of NOG was increased to 1.7:1 molar ratio, the DS was
increased to 3.99%. HA-NOG with 3.99% DS was used for all subsequent studies.
3.3.2 Enzymatic Release of NOG from HA-NOG Conjugate
Release of NOG from HA-NOG was evaluated during chemical and enzymatic
hydrolysis. Enzymatic degradation of HA-NOG was expected to be the primary
mechanism for NOG release. HA-NOG was incubated in PBS, PBS with Ease, and PBS
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with Ease and Hase for 7 days (Figure 3.2). Incubation in PBS alone resulted in 7%
cumulative NOG release over 7 days, with no significant differences in the amount of
NOG released between any days within that span. In the presence of Ease alone and
Ease/Hase, NOG release was significantly increased at all time points relative to PBS
alone, with 78% and 90% released by day 3, respectively, and 93% and 99% released
by day 7. Both conditions resulted in significant increases in NOG concentration each
day from day 0 to day 3, while Ease alone also significantly increased from day 3 to
day 4.

Figure 3.2. Release of NOG in the absence and presence of Ease and Hase at 37ºC over
7 days.

3.3.3 Evaluation of Angiogenic Bioactivity
3.3.3.1 HIF-1α Stabilization
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From the DS of HA-NOG, we calculated that 72μM HA-NOG would contain
10μM NOG. HIF-1 protein was undetectable by immuno-staining in NHDF cultures
that were untreated (data not shown) or exposed to native HA (Figure 3.3). NHDF
treated with free NOG, HA-NOG, or exposed to hypoxia (Figure 3.3) or CoCl2 (data
not shown) exhibited positive staining for HIF-1 localized to the cell nucleus.

Figure 3.3. Immunocytochemical analysis of HIF-1α stabilization in NHDF for HA,
HA-NOG, NOG, and hypoxia at 6 hours. DAPI stain (blue) was used as a control to
compare against HIF-1α accumulation (green) within the nucleus. (Scale bar =
200μm).

3.3.3.2 Expression of HIF-1α Target Genes
Expression of each target gene significantly increased for HA-NOG, NOG, and
hypoxia conditions when compared to the HA and untreated controls (Figure 3.4A).
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VEGF, GLUT1, and PHD2 all exhibited 3-5 fold increases expression for all three
conditions. Consistent with qualitative observations of HIF-1 stabilization, there were
no significant differences observed between HA-NOG, NOG, and hypoxia positive
control for any of the target genes, further confirming the ability of the HA-NOG
macromolecular prodrug to activate the hypoxia response. We also investigated the
effect of HA-NOG concentration on target gene expression. mRNA expression
increased with increasing HA-NOG in a dose-dependent manner and was significantly
higher for all targets at 18μM, 36μM, and 72μM (2.5μM, 5μM, and 10μM NOG,
respectively) relative to the untreated control (Figure 3.4B). Expression levels were
not significantly different for 7.2μM (1μM NOG) HA-NOG.

Figure 3.4. Relative mRNA expression levels of angiogenic target genes: VEGF,
GLUT1, and PHD2. NHDF were incubated in experimental conditions of A) HA, HANOG, NOG, and hypoxia, and an untreated control, and B) HA-NOG (7.2μM, 18μM,
36μM, and 72μM) for 6 hours. Statistical comparisons between groups are indicated
as * (p < 0.05).
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3.3.3.3 Tubulogenesis Analysis
Tube formation was limited in cells cultured with conditioned medium from
the untreated (data not shown) and HA-treated NHDF (Figure 3.5A) negative control
groups. Substantially increased tubule formation was observed in cells receiving
conditioned medium from NHDF cultured with NOG, HA-NOG, hypoxia (Figure 3.5BD), and CoCl2 (data not shown). Measurements of tubule length further quantitatively
confirmed significant increases in tubulogenesis for NOG, HA-NOG, hypoxia, and
CoCl2 conditioned medium groups compared to the untreated and HA-treated groups
(Figure 3.5E). There were no significant differences among HA-NOG and NOG groups
and the positive controls.
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Figure 3.5. Tubulogenesis analysis of HUVECs with A) total tubule length of HUVECs
cultured with B) HA, C) HA-NOG, D) NOG, and E) hypoxia for 6 hours on Matrigel
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(untreated and CoCl2 not shown). Total tubule length was measured using ImageJ
software. Statistical comparisons between experimental groups and the untreated
group are indicated as * (p < 0.05) (Scale bar = 200µm).

3.3.4 Cytotoxicity
After 5 days culture, metabolic activity measured by the alamarBlue assay was
not significantly different between HA-NOG and NOG and untreated and HA-treated
negative control groups (Figure 3.6A). Similarly, an analysis of hydroxyproline
content showed that there was no significant change for any experimental condition
when compared to the untreated and HA-treated controls, as well (Figure 3.6B). In
addition, there were significant differences in DNA content among the treatment
groups measured for normalization of hydroxyproline content (data not shown).

Figure 3.6. A) Metabolic activity and B) hydroxyproline content of NHDF cultured in
HA, HA-NOG, and NOG, and an untreated control for 5 and 14 days, respectively. No
statistically significant difference was observed between experimental groups, HA,
HA-NOG, and NOG, and the untreated control group.
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3.4 DISCUSSION
Successful use of bioactive small molecules in regenerative medicine still has
several challenges to overcome, most notably limited solubility of hydrophobic drugs
and rapid clearance of hydrophilic drugs, making it difficult to achieve a therapeutic
dose at the target site while minimizing systemic side effects. The goal of this study
was to develop N-oxalylglycine (NOG) hyaluronic acid (HA-NOG) as a
macromolecular prodrug that can be incorporated within hydrogels for the localized
activation of therapeutic angiogenesis. We hypothesized this approach would allow
hydrophilic NOG to be stably sequestered within hydrogels and released in a
localized, sustained manner in response to cellular enzymatic activity.
3.4.1 Enzymatic Release of NOG from HA-NOG Conjugate
The results of the release study demonstrate that despite conjugation through
a double ester, HA-NOG is relatively stable in physiological buffer. HA has commonly
been used as a backbone for macromolecular prodrugs in order to increase the
aqueous solubility of hydrophobic drugs, target drugs to cancers overexpressing HA
receptors, and increase circulation/residence time

184.

The time required for drug

release varies from days to weeks, likely depending upon the drug physicochemical
properties, conjugation chemistry, and adjacent chemical structures, such as spacer
groups

182,262,269,270.

Our results demonstrate that HA-NOG is relatively stable in

physiological buffer, consistent with previous observations of HA-DXM conjugated in
a similar manner 185. This suggests that when incorporated into hydrogels, HA-NOG
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will be able to sequester hydrophilic NOG within the network until released in
response to cellular enzymatic activity.
3.4.2 Evaluation of Angiogenic Bioactivity
3.4.2.1 HIF-1α Stabilization
To evaluate the ability of HA-NOG to activate the angiogenic response in target
cells, we first investigated its ability to stabilize the HIF-1 subunit that is
constitutively degraded under normoxic conditions. HA-NOG was compared to NOG
alone (free drug); untreated and native HA as negative controls; and CoCl2 and
hypoxia as positive controls. 10μM NOG was chosen based on previous reports
demonstrating that this concentration was effective for inhibition of PHD2 and FIH
and stabilization of HIF-1199,251
There was no observable difference in HIF-1 expression between HA-NOG
and the positive controls, demonstrating the conjugate’s efficacy in stabilizing HIF1. Since high molecular weight HA cannot passively cross the cell membrane, there
are several possible mechanisms by which NOG may reach the cytoplasm and prevent
HIF-1 degradation. One possibility is that esterase enzymes present in the serumcontaining culture medium may release NOG, allowing the free drug to diffuse across
the cell membrane. Alternatively, HA-NOG may be actively internalized either
through basal endocytosis/pinocytosis or during degradation by membraneassociated hyaluronidase 271. The first reports investigating the role of PHDs and FIH
in HIF-1 stability demonstrated that NOG inhibited the activity of isolated enzymes,
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but used the more hydrophobic derivative DMOG for cell culture studies

79,82.

This

was based upon the notion that DMOG would have superior membrane transport, and
although a direct comparison of NOG and DMOG was not reported, DMOG has been
used almost exclusively since. Interestingly, in our studies, NOG added to the culture
medium as a free drug showed comparable efficacy for HIF-1 stabilization as HANOG and the CoCl2 / hypoxia positive controls. Therefore, both mechanisms
proposed above involving extracellular and intracellular NOG release may contribute
to the ability of HA-NOG to stabilize HIF-1.
3.4.2.2 Expression of HIF-1 Target Genes
In the physiological hypoxia response, stabilized HIF-1 joins with the HIF-1
subunit, binds to HRE domains and activates transcription of a wide range of hypoxiaresponsive genes. Therefore, we next investigated mRNA expression levels of VEGF,
GLUT1, and PHD2; three direct targets of HIF-1 that mediate the hypoxia response by
activating endothelial cells, increasing glucose transport, and putatively initiating
negative feedback 21,272,273.
As noted above, other studies investigating NOG-based activation of HIF-1
have used the DMOG derivative based on its expected higher cell permeability.
Interestingly, DMOG has been used at substantially higher concentrations than the
10μM concentration of NOG used as free drug or prodrug conjugate in the present
study. In one of the earliest studies, Jaakkola et. al. tested 0.1 and 1 mM DMOG in cellbased assays and found that 1 mM substantially increased HIF-1 expression
detectable by Western blot 82. More recently, several reports have investigated dose67

dependent effects of DMOG on HIF-1 stabilization and activation of target gene
mRNA expression in various types of mesenchymal stem cells

83,274,275.

Responses

consistently increased with increasing DMOG concentration and were significantly
higher at 0.5 and 1 mM compared to 0.2 mM or untreated. Therefore, NOG is able to
activate HIF-1 target gene expression at levels not significantly different from hypoxia
positive control at 2 orders of magnitude lower concentration (10μM) than that at
which DMOG is conventionally used (1 mM).
3.4.2.3 Tubulogenesis Analysis
HIF signaling, whether activated directly by hypoxia or indirectly by
exogenous stimuli such as NOG, culminates in the release of pro-angiogenic growth
factors that act on surrounding cells to initiate angiogenesis. In these studies, we used
endothelial cell tubulogenesis as an in vitro angiogenesis assay to investigate the
presence of pro-angiogenic growth factors in conditioned medium from NHDF
cultured in the presence of HA-NOG and various control conditions 276,277.
Tube formation in cell culture is the most common method to determine if
angiogenic-like conditions are being expressed in vitro. Many studies have utilized
this method to verify angiogenic and anti-angiogenic activity of small molecules for
regenerative medicine. Shen et. al. studied the effect of small molecules, DFO and Lmimosine (L-mim) on HIF-1α stabilization in BMSCs and subsequent tube formation
of HUVECs, with 50μM DFO and 300μM L-mim both producing significant increases
in tube-like structures without showing any obvious signs of cell death 61. Side effects
of DFO and L-mim at the stated concentrations were not explored further in the study.
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Use of DFO above 30μM, however, has been shown to be toxic to cells, even
differentiating them to cancerous cell types, as mentioned previously. Released NOG
from HA-NOG is a strong HIF-1α stabilizer and pro-angiogenic small molecule with a
lower effective concentration than most other small molecules tested in the same
capacity. It is worth noting again that its effectiveness remains on par with the
positive controls chosen for the study. The results of this study verified that HA-NOG
activates the HIF-1 signaling pathway, leading to the secretion of pro-angiogenic
signaling molecules that can activate endothelial cells to initiate therapeutic
angiogenesis.
3.4.3 Cytotoxicity
In addition to its central role in oxygen-sensing, HIF-1 activity can also be
regulated by extracellular growth factors and cytokines and the activity of other
intracellular signaling pathways 278,279. Additionally, the HIF PHDs and FIH are
members of a large family of 2-oxoglutarate-dependent dioxygenases including
prolyl-4-hydroxylases critical for collagen synthesis and a histone demethylases
involved in chromatin modification and transcriptional regulation 251,280. Therefore,
exogeneous activation of the HIF pathway, particularly through inhibition of PHDs,
may have detrimental effects on cell health and function. As first step towards
assessing safety, we investigated the effect of HA-NOG on NHDF metabolic activity
and accumulation of insoluble collagen matrix.
Collectively, the metabolic activity and DNA content data indicate that
exposure to HA-NOG does not adversely affect cell viability or proliferation. This

69

contrasts with previous studies using DMOG that observed inhibition of cell
proliferation 83,274. The hydroxyproline analysis indicates that HA-NOG, at least at
the concentration used in these studies, does not interfere with collagen synthesis
and extracellular deposition. This is perhaps surprising, given that previous studies
have shown NOG to be an effective inhibitor of prolyl-4-hydroxylase (P4H) that is
responsible for formation of hydroxyproline that is essential for formation of the
collagen triple helix 281. Recently, Bentovim et. al. investigated the mechanisms
underlying collagen synthesis in the hypoxic environment of cartilaginous growth
plates 282. They found that hypoxia increased the mRNA expression of the 3 subunits
that comprise P4H, as well as confirming the presence of HRE in the promoter of the
pyruvate dehydrogenase kinase 1 (Pdk1) gene. They proposed a model for how
growth plate chondrocytes achieve collagen synthesis under hypoxia that included
increasing both the enzyme and substrate for proline hydroxylation, through HIF-1dependent increased P4H expression and Pdk1-medidated inhibition of the
tricarboxylic acid cycle to reduce cellular oxygen consumption. This model offers
one potential explanation for how HA-NOG is able to stabilize HIF-1 and initiate
pro-angiogenic signaling without interfering with collagen metabolism. Although
the exact mechanism remains uncertain, our results suggest that HA-NOG can
activate the HIF-1 pathway without negatively impacting cellular health or an
essential and closely related metabolic pathway.

3.5 CONCLUSION
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N-oxalylglycine-conjugated hyaluronic acid (HA-NOG) was successfully
synthesized and characterized. NOG was released from the conjugate by cellmediated enzymatic degradation and influenced the accumulation of the master
transcription factor HIF-1α in the nucleus of cells. This led to the expression of proangiogenic target genes and subsequent endothelial cell tubulogenesis. HA-NOG was
as effective as NOG, as well as other HIF-1α stabilizing conditions, when added
directly to cell culture medium in stimulating an angiogenic response without
inducing negative side effects. These results show that HA-NOG conjugate can serve
as a safe and effective method of local, sustained release of NOG for treatment of
ischemia. In terms of future applications, this method could also be used in the
treatment of other pathologies by simply replacing the conjugated small molecule.
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CHAPTER FOUR
AIM II: EVALUATION OF RELEASE KINETICS AND BIOACTIVITY OF NOG FROM
POLY(ETHYLENE GLYCOL) DIACRYLATE/HYALURONIC ACID SEMI-IPNS

4.1 INTRODUCTION
One major challenge with stimulating therapeutic angiogenesis is the
sustained and localized delivery of the therapeutic agent (i.e., genes, proteins, small
molecules) being utilized. As described previously, macromolecular prodrugs can
provide one layer of protection against premature small molecule degradation, but
this does not guarantee proper sustained release or prevent degradation entirely
283,284.

Novel delivery systems for therapeutics are necessary to achieve

therapeutically effective concentrations in the target tissue, while minimizing
adverse side effects. Various biomaterial-based scaffolds, including polymeric
microspheres and hydrogels have been used for entrapment and controlled release
of therapeutics

103,143.

However, both approaches have limitations that need to be

respected. Microspheres are most commonly fabricated from relatively hydrophobic,
degradable polyesters, such as poly(lactide-co-glycolide) 285,286. Although successful
in some applications, challenges include burst release of poorly entrapped small
molecules, inefficient loading of hydrophilic drugs, and release kinetics that are
controlled by polymer chemistry with little responsiveness to the biological
environment 287,288. Hydrogels face important limitations, like the difficulty to include
non-polar small molecules within their matrix and the inability to keep polar small
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molecules from releasing too quickly 289,290. Despite these limitations, scaffold-based
delivery of exogenous therapeutics remains popular in drug delivery, as it can bolster
protection from degradation while also providing key bioactive properties for cellmediated degradation and remodeling.
Hydrogels are highly hydrophilic, yet water insoluble, crosslinked structures
formed from natural and/or synthetic polymers that have been used as bioadhesives,
wound dressings, and contact lenses, as well as delivery systems and tissue scaffolds
291–293.

The crosslinking of polymeric monomers/macromers creates a highly

structured matrix resistant to dissolution, while exhibiting similar flexibility to
natural tissue. Poly(ethylene glycol) (PEG) is a well-studied and commonly used
biocompatible material in hydrogel formulations for biomedical applications,
including scaffolds for tissue engineering and controlled therapeutics release
206,294,295.

Chemical modification of PEG has been used to expand its capabilities in

crosslinking with other macromers, and can also be covalently attached to
macromolecules to improve the pharmacokinetic/pharmacodynamic properties, in a
process known as PEGylation

296,297.

Previous work in the lab demonstrated the

efficacy of PEG derivatives, PEG-bis-(acryloyloxy acetate) (PEG-bis-AA), PEG-bis(acryloyloxy propanoate) (PEG-bis-AP), and PEG-bis-(acryloyloxy butyrate) (PEGbis-AB) hydrogels for controlled release 185,208,209. Hydrogels formed from these PEG
derivatives hydrolytically degrade at various rates, while blending the derivatives in
different concentrations can alter the rate of degradation. Being able to vary the rate

73

of hydrogel degradation allows for better control of drug release in situations that
may require faster or slower release and uptake.
Recently, several research groups have begun to employ a bilayer hydrogel
approach, combining two distinct hydrogel layers into one delivery system to take
advantage of the unique mechanical and bioactive properties of the individual
materials

298–300.

In drug delivery, providing a fast initial therapeutically effective

dose that can also be sustained over an extended period of time is challenging without
overdosing and maintaining a prolonged supraphysiological response. Activation of
the angiogenic pathway for injury treatment requires a quick initiation with
sustained pro-angiogenic gene expression to form new revascularized tissue

301.

Overdosing of locally delivered pro-angiogenic drugs creates an issue with potential
tumorigenesis, both benign and malignant

302–304.

To prevent this, careful attention

needs to be paid to the rate of delivery after the initial onset of angiogenesis. Utilizing
a bilayer hydrogel model containing a fast degrading first layer and a moderately slow
degrading second layer can, in theory, provide quick initiation with sustained
activation. Herein, we describe the crosslinking of PEGdA/HA-NOG semi-IPN singlelayer and bilayer hybrid hydrogels for local, sustained delivery of pro-angiogenic
NOG. The objectives of these studies were to demonstrate NOG release from singlelayer hybrid hydrogels, as shown previously with HA-DXM 185, develop a new bilayer
hybrid hydrogel containing fast-degrading PEG-bis-AA and moderately-degrading
PEG-bis-AP, and demonstrate the ability of NOG released from bilayer hydrogels to
stabilize HIF-1α and increase expression of HIF-1α target genes.
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4.2 MATERIALS AND METHODS
4.2.1 Materials
Hyaluronic acid (HA, sodium salt, MW 1.5 MDa) and PEG diol (4kDa) were
purchased from LifeCore Biomedical (Chaska, MN) and Fluka (Buchs, Switzerland),
respectively. Carbonyldiimidazole (CDI), triethylamine (TEA), sodium acrylate, 2chloropropionyl

chloride,

chloroacetyl

chloride,

dimethylsulfoxide

(DMSO),

dimethylformamide (DMF), dichloromethane (DCM), ethyl ether, chloroform, and 4methoxyphenol were purchased from Sigma-Aldrich (St. Louis, MO). Tetrabutyl
ammonium bromide (TBA-Br) and Dowex 50WX8 200−400(H) were purchased from
Alfa Aesar (Ward Hill, MA). N-oxalylglycine (NOG) was purchased from Cayman
Chemical (Ann Arbor, MI). Normal human dermal fibroblasts (NHDF) were purchased
from Lonza (Walkersville, MD). Dulbecco’s modified Eagle medium (DMEM) and
bovine growth serum (BGS) were purchased from Corning Life Sciences (Tewksbury,
MA).
4.2.2 Synthesis and Characterization
4.2.2.1 PEG-bis-AA and PEG-bis-AP Macromers
PEG-bis-(acryloyloxy

acetate)

(PEG-bis-AA)

and

PEG-bis-(acryloyloxy

propanoate) (PEG-bis-AP) were synthesized by a two-step reaction as previously
described

209.

PEG hydroxyl groups were reacted with chloroacetyl acetate or 2-

chloropropionyl

chloride

to

form

PEG-bis-(chloroacetate)

or

PEG-bis-(2-

chloropropanoate), respectively. Intermediate products were reacted with sodium
acrylate and dried to obtain PEG-bis-AA and PEG-bis-AP powders. The structure and

75

degree of acrylation of the final products were determined by 1H NMR (CDCl3) as
previously described 209.
4.2.2.2 HA-NOG Conjugate
N-oxalylglycine-conjugate hyaluronic acid (HA-NOG) was synthesized by a
two-step reaction as previously described. Briefly, the terminal carboxyl group of Noxalylglycine (NOG) was activated with 1,1’-carbonyldiimidazole (CDI), then the
activated NOG was conjugated to the hydroxyl groups of HA-TBA in the presence of
TEA to obtain HA-NOG.
4.2.2.3 Semi-IPN Polymerization
PEG-bis-AA (30% w/v) and PEG-bis-AP (30% w/v) macromers and native HA
(4% and 2% w/v) and HA-NOG (4% and 2% w/v) were prepared in 0.1M PBS (w/out
Ca+2, Mg+2, pH 7.4). To prepare monolayer semi-IPNs (Table 4.1), 25μL solutions of
6% PEG-bis-AA/0.72% HA, HA (+7.2μg NOG), or HA-NOG, or PEG-bis-AP/HA, HA
(+7.2μg NOG), or HA-NOG, and Irgacure 2959 (I-2959, 0.1% w/v) (all final
concentrations) were prepared. Semi-IPN hydrogel discs were photopolymerized as
previously described with 0.5mm Teflon spacers. To prepare bilayer semi-IPNs
(Table 4.1), 25μL solutions of 6% PEG-bis-AP/0.36% HA-NOG + 6% PEG-bisAA/0.36% HA-NOG, 6% PEG-bis-AP/0.36% HA + 6% PEG-bis-AA/0.36% HA, or 6%
PEG-bis-AP/0.36% HA (+3.6μg NOG) + 6% PEG-bis-AA/0.36% HA (+3.6μg NOG). All
semi-IPN solutions contained I-2959 (0.1% w/v). The PEG-bis-AA layer (12.5μL) of
each semi-IPN hydrogel disc was photopolymerized between glass coverslips
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separated by 0.25mm Teflon spacers for 3min, then increased to 0.5mm with the PEGbis-AP layer (12.5μL) added to finish polymerizing for 7min.

Table 4.1: Compositions of PEGdA hybrid hydrogels consisting of either
a hybrid monolayer or a hybrid bilayer, with entrapped free NOG or entrapped
HA or HA-NOG.
Monolayer Gels
PEG-bis-AA
6% PEG-bis-AA/0.72% HA
6% PEG-bis-AA/0.72% HA + 7.2μg
NOG
6% PEG-bis-AA/0.72% HA-NOG
(7.2μg NOG)

PEG-bis-AP
6% PEG-bis-AP/0.72% HA
6% PEG-bis-AP/0.72% HA + 7.2μg
NOG
6% PEG-bis-AP/0.72% HA-NOG
(7.2μg NOG)

Bilayer Gel
PEG-bis-AA + PEG-bis-AP
6% PEG-bis-AA/0.36% HA
6% PEG-bis-AP/0.36% HA
6% PEG-bis-AA/0.36% HA + 3.6μg
6% PEG-bis-AP/0.36% HA + 3.6μg
NOG
NOG
6% PEG-bis-AA/0.36% HA-NOG
6% PEG-bis-AP/0.36% HA-NOG
(3.6μg NOG)
(3.6μg NOG)
4.2.2.4 Release of N-oxalylglycine from Semi-IPNs In Vitro
NOG release from HA-NOG entrapped within bilayer semi-IPNs was evaluated
in physiological buffer alone and with the addition of hydrolytic enzymes such as
hyaluronidase (Hase) and esterase (Ease). HA-NOG was incubated in 0.1M PBS (pH
7.4) solution, 0.1M PBS containing Ease (5 U/mL), and 0.1M PBS containing Ease and
Hase (5 U/mL each) at 37°C. Samples (100μL) of each solution were removed and
replenished at 1, 8, and 24 hours, and each day thereafter for 24 days and stored at
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−20°C until analysis. To quantify the release of NOG from HA-NOG after incubation in
the PBS, PBS/Ease, and PBS/Ease/Hase solutions, UV spectrophotometry was
performed. Samples (20μL) were treated with methanol (80μL), centrifuged, and
filtered using a 0.2μm syringe filter. The concentration of released NOG was
measured

by

absorbance

at

220nm

using

a

NanoDrop

2000c

UV-Vis

Spectrophotometer (Thermo Fisher) with a standard curve of NOG prepared by serial
dilution.
4.2.3 Evaluation of Angiogenic Bioactivity
4.2.3.1 Cell Culture
Cell culture for in vitro analysis was performed using NHDF. NHDF cell culture
medium consisted of DMEM/F-12 50/50 mix with L-glutamine (Corning)
supplemented with HyClone bovine growth serum (GE Healthcare) and penicillin
streptomycin solution (Corning).
4.2.3.2 Expression of HIF-1α Target Genes
Photopolymerized bilayer semi-IPNs containing HA (0.72% total), HA-NOG
(0.72%, 7.2μg total), and HA with free NOG (0.72%, 7.2μg total) were incubated in
serum-free DMEM/F-12 containing Ease and Hase (5 U/mL each) at 37°C for 3,7, and
14 days, and stored at -80°C until use. NHDF were seeded onto 6-well plates (300,000
cells/well) and cultured with unconditioned DMEM/F-12 for 24 hours. The medium
was exchanged and the cells were then cultured for 6 hours with bilayer semi-IPN
conditioned medium. Cells were lysed with TRIzol Reagent (Ambion) and the
aqueous phase transferred to RNeasy columns (Qiagen) for purification. Isolated RNA
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was treated with DNase using TURBO DNA-free kit (Invitrogen). A Take 3 microplate
reader (Biotek Instruments) was used to determine quantity and quality of isolated
RNA. Purified RNA (1μg) was reverse transcribed with a High Capacity cDNA RT kit
(Applied Biosystems) and real-time qRT-PCR was performed using PowerUp SYBR
Green Master Mix (AB) with custom sense and anti-sense primers (5μM) for β-2
microglobulin (β2MG, housekeeping gene), vascular endothelial growth factor
(VEGF), glucose transporter 1 (GLUT1), and prolyl hydroxylase domain 2 (PHD2)
(Table 3.1) using a Rotor-Gene Q thermal cycler (Qiagen). Relative mRNA expression
levels were quantified by the 2-ΔΔCt method with results expressed as relative fold
changes.
4.2.4 Statistical Analysis
Statistical comparisons were performed using one-way analysis of variance
(ANOVA). P-values less than 0.05 were considered significant. Data are expressed as
mean +/- standard deviation with significant differences marked as * (p < 0.05).
4.3 RESULTS
4.3.1 Enzymatic Release of NOG from PEGdA/HA Hydrogels
PEG-bis-AA, PEG-bis-AP, and a bilayer PEG-AA/PEG-AP were crosslinked with
HA-NOG and incubated in PBS, PBS with Ease, and PBS with Ease and Hase for 24 days
(Figure 4.1). Analysis of 24-day release samples showed that incubation in PBS alone
resulted in <15% released during the span. This resistance to chemical degradation
further demonstrates the stability of the HA-NOG conjugate from the previous study.
In the presence of Ease alone and Ease/Hase, NOG was released in a greater capacity
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than in PBS alone and followed similar release profiles to previous studies looking at
the rate of hydrogel degradation and release of a crosslinked conjugate. PEG-AA/HANOG showed NOG release over 80% of the total amount by day 7 for both Ease and
Ease/Hase, while PEG-AA samples crosslinked with free NOG released the same
amount by day 4. PEG-AP/HA-NOG showed NOG release over 80% by day 18 for both
Ease and Ease/Hase, while PEG-AP samples crosslinked with free NOG released the
same amount by day 8 The bilayer PEG-AA/PEG-AP/HA-NOG hydrogel demonstrated
release properties of the individual PEGdA components that comprised it.
Bilayer/HA-NOG hydrogels incubated with Ease exhibited slower release by day 4
(~20% release), but increased release for days 5-7 (~60% release). Bilayer/HA-NOG
incubated in Ease/Hase showed a quicker release within the first 4 days (~60%
release), followed by a slower release of NOG over the next 9 days. Bilayer hydrogels
with free NOG demonstrated quick release over the first 7 days, with over 80%
release by day 7. Compared to the release studies in Aim I, the rate of release of NOG
from the conjugate alone is 75% faster than the rate of release when entrapping the
conjugate within a hydrogel.
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Figure 4.1. Release of NOG from A) PEG-AA/HA-NOG, B) PEG-AA/HA (+NOG), C) PEGAP/HA-NOG, D) PEG-AP/HA (+NOG), E) Bilayer/HA-NOG, and F) Bilayer/HA (+NOG)
hydrogels in the presence and absence of Ease and Hase over 24 days.

4.3.2 Evaluation of Angiogenic Bioactivity
Expression of VEGF was significantly different at days 3, 7, and 14 for the
bilayer/HA-NOG hydrogel over the bilayer/HA negative control (Figure 4.2). The
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study showed significantly increased expression fold changes between days 3 and 7,
but no significant change between days 7 and 14 for the bilayer/HA-NOG hydrogel.
Bilayer/HA (+NOG) positive control showed a significant difference at day 3 over the
bilayer/HA hydrogel, but decreased expression between days 3 and 7, and
significantly decreased expression between days 7 and 14. There was no significant
difference at day 14 over the negative control for the bilayer/HA (+NOG). At day 14,
the bilayer/HA-NOG had a nearly 3-fold expression change over the bilayer/HA
(+NOG) hydrogel at 4.1 expression fold change. Expression of GLUT1 also
significantly increased at days 3, 7, and 14 for the bilayer/HA-NOG hydrogel over the
negative control, with a significant increase between days 3 and 7, but no significant
change between days 7 and 14. Bilayer/HA (+NOG) showed a significant difference at
days 3, 7 and 14 over the bilayer/HA hydrogel and a significant difference over the
bilayer/HA-NOG hydrogel at day 3 but decreased significantly between each time
point. By day 14, the bilayer/HA-NOG hydrogel had a 2.5-fold expression change
difference over the bilayer/HA (+NOG) hydrogel. Expression of PHD2 was
significantly different at all three time points for the bilayer/HA-NOG hydrogel over
the negative control, with significantly increasing expression between bilayer/HANOG groups at days 3 and 7, but no significant change between days 7 and 14.
Bilayer/HA (+NOG) showed a significant difference at days 3, 7, and 14 over the
negative control and had a higher expression fold change at day 3 compared to the
bilayer/HA-NOG hydrogel, but this was not statistically significant. Expression fold
change for bilayer/HA (+NOG) decreased significantly between days 3 and 7, but not

82

between days 7 and 14. By day 14, the bilayer/HA-NOG hydrogel had a 2-fold
expression change difference over the bilayer/HA (+NOG) hydrogel. These results
show that released NOG from PEGdA/HA-NOG hydrogels can stimulate a longer proangiogenic response than unconjugated NOG through prolonged stabilization of HIF1α without causing excessive overexpression of growth factors.

Figure 4.2. Relative mRNA expression levels of angiogenic target genes A) VEGF, B)
GLUT1, and C) PHD2, exposed to bilayer hybrid hydrogels containing HA (0.72%),
HA-NOG (0.72%, 7.2ug NOG), and HA (+NOG, 7.2ug) and incubated up to 14 days.
Statistical comparisons between groups are indicated as * (p < 0.05), ** (p < 0.01), or
ns (p > 0.05).
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4.4 DISCUSSION
The goal of this study was to develop an optimized hybrid hydrogel system for
delivery of a macromolecular prodrug containing a conjugated pro-angiogenic small
molecule to induce therapeutic angiogenesis in ischemic tissue. Delivery of small
molecules can be difficult due to the insolubility (hydrophobic) or ineffective
entrapment (hydrophilic) of the molecules used, leading to inconsistencies in dosing
if not properly delivered via a delivery system. PEGdA derivatives, PEG-bis-AA, PEGbis-AP, and PEG-bis-AB, allow for sustained release of entrapped molecules and can
be blended to fine tune the release profile for various time-dependent therapies.
Incorporating the macromolecular prodrug, HA-NOG, into a blended PEGdA hydrogel
offers a precise delivery method to stimulate local angiogenesis in a controlled
manner to prevent ineffective dosing or excessive overexpression.
4.4.1 Enzymatic Release of NOG from PEGdA/HA-NOG Hydrogels
Release of NOG from PEGdA/HA-NOG hydrogels was evaluated by chemical
and enzymatic hydrolysis. Enzymatic degradation of HA-NOG within PEGdA/HA-NOG
hydrogels was expected to be the mechanism for release of NOG, based on a previous
study demonstrating release of NOG from the HA-NOG conjugate alone. Bae et. al.
conjugated DX, a hydrophobic small molecule to HA by a double ester bond using a
short succinic anhydride spacer to help with solubility and resist chemical hydrolysis
to allow for enzymatic degradation and entrapped this in crosslinked PEGdA
derivatives to control the release of DX

185.

In contrast to this, we covalently

conjugated NOG, a hydrophilic small molecule, to HA to help reduce the chance of
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burst release, and crosslinked HA-NOG with PEGdA derivatives capable of variable
release rates.
The rate of release for both PEGdA derivatives closely follows what was
observed in previous studies using the same hydrogel components and
macromolecular backbone for the delivery of dexamethasone (DX, HA-DXM)

185,215.

Slowing down the release of NOG can help reduce the chance of overexpression of
pro-angiogenic target genes, which can adversely affect adjacent HIF-targeting
pathways and could also lead to tumorigenesis. This study confirmed that the
mechanism of release for NOG from PEGdA/HA-NOG hydrogels was enzymatically
driven and entrapping the conjugate within a crosslinked hydrogel matrix could help
control the rate of release.
4.4.2 Evaluation of Angiogenic Bioactivity
Previous studies have shown that NOG released from an HA-NOG conjugate
alone could increase expression of pro-angiogenic and HIF-related target genes in
NHDF within 6 hours. To further examine the HIF-1α stabilizing capabilities of HANOG, the conjugate was entrapped with crosslinked PEGdA derivatives, PEG-bis-AA
and PEG-bis-AP, in a bilayer hydrogel and incubated in culture conditions for 14 days.
Samples sets containing bilayer/HA and bilayer/HA (+NOG) were used as negative
and positive controls, respectfully. mRNA expression level differences were
quantified for VEGF, GLUT1, and PHD2, all known targets of HIF-1α. VEGF and GLUT1
served as the pro-angiogenic target genes to highlight the bioactive capabilities of HANOG, while PHD2 served as the metric for determining if NHDF were expressing
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increased PHDs in response to elevated levels of HIF-1α. The goal of this study was to
determine if the release of NOG from the bilayer/HA-NOG hydrogel could stimulate
and sustain increased expression of HIF-1α target genes at expression levels suitable
for angiogenesis.
Artificially stimulating angiogenesis is not without risk, as angiogenesis is
linked to every major organ system and is a necessary function for tissue repair in
adults. Excessive overexpression of angiogenic growth factors can most notably lead
to cancerous tumor formation, making the rate of expression the most important
property to monitor in these studies. VEGF expression, although steadily increasing,
was not excessive by day 14 for the bilayer/HA-NOG hydrogel. The decreasing
expression seen from the bilayer/HA (+NOG) hydrogel suggests that VEGF expression
would begin to slow down or decrease after 14 days for the bilayer/HA-NOG
hydrogel. This suggestion is substantiated by the slight decrease in PHD2 expression
at day 14 for the bilayer/HA-NOG hydrogel, as cells would begin to transition out of
the pseudo-hypoxic state and the positive feedback causing an increase in PHD2
expression would be reduced. GLUT1 expression also slowed down by day 14 for the
bilayer/HA-NOG hydrogel, further verifying that cells were beginning to transition
back to a normoxic environment.
4.5 CONCLUSION
PEGdA/HA-NOG hydrogels were successfully polymerized and characterized
for the release of NOG. NOG was released from the PEG-bis-AA, PEG-bis-AP, and PEGAA/PEG-AP bilayer hydrogels by cell-mediated degradation at various rates. PEG-bis-
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AA hydrogels released NOG the fastest, while PEG-bis-AP hydrogels released NOG the
slowest. The bilayer hydrogels showed characteristics of the two PEGdA derivatives
that comprised it and released NOG quickly for several days before slowing down
release over the next week. Bilayer hydrogels also stimulated increased expression of
HIF-1α target genes, VEGF, GLUT1, and PHD2, verifying that the concentration of
conjugated NOG in the hydrogels could administer an effective dose.

87

CHAPTER FIVE
AIM III: EVALUATION OF AN ALTERNATIVE PURIFICATION METHOD FOR
GELATIN METHACRYLATE BY ACETONE PRECIPITATION

5.1 INTRODUCTION
Biomaterials for tissue engineering are generally chosen based on their
biocompatibility and ability to provide biochemical cues that support cell growth and
survival. Collagen, an extracellular matrix (ECM) protein, and gelatin, a derivative of
type I collagen, are widely used in tissue engineering as biomimetic materials,
particularly as films, sponges, nanoparticles, and hydrogels in wound dressing, tissue
graft, and drug delivery applications

305–308.

Collagen and gelatin exhibit very little

immunogenicity due to being naturally derived, possessing integrin-binding
sequences to support cell adhesion, while also being intrinsically susceptible to cellmediated proteolytic degradation, resulting in a valuable set of characteristics for
scaffold applications

309.

These materials, however, are limited in their use due to

rapid degradation that is difficult to control without introducing cytotoxic
crosslinkers 310. A solution to overcoming this challenge was the synthesis of gelatin
methacrylate (GelMA) by Van Den Bulcke et. al., who found that modifying gelatin
with covalently-crosslinking methacrylate groups could alter its mechanical and
degradation properties without sacrificing biocompatibility 180. GelMA, also referred
in literature as gelatin methacryloyl, methacrylated gelatin, gelatin methacrylamide,
or methacrylamide modified gelatin, is a versatile material that can easily be tuned
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by changing the degree of methacrylate functionalization 180,311–314, and has recently
drawn significant attention from research groups utilizing GelMA in 3D bioprinting
for creating cell- and drug-loaded, and naked scaffolds 315–318.
As of today, the current methods for synthesizing GelMA involve a lengthy
dialysis and lyophilization process that can significantly slow down or hinder
research groups wanting to evaluate various experimental formulations

219.

At the

academic level, this can be a major issue, but may not translate as being as hindering
at the industrial level. The objective of this technical note is to present an alternative
method for precipitating GelMA that drastically reduces the overall synthesis and
recovery time from ~7-10 days to 2-3 days. Outlined below are the procedures
detailing the precipitation of GelMA using acetone that include several redissolution
and precipitation steps to ensure proper purification. Characterization of the
structural, mechanical, and bioactive properties were assessed for acetone
precipitated GelMA samples and compared against samples synthesized by the
traditional dialysis method. The goal of these assessments was to evaluate the
differences, if any, in the products of the two GelMA purification methods and
determine if acetone precipitation is a viable alternative method.
5.2 MATERIALS AND METHODS
5.2.1 Materials
Gelatin from porcine skin (Type A), methacrylic anhydride (MA), 2mercaptoethanol, ninhydrin, sodium citrate monobasic, glycerol, and acetone were
purchased from Sigma-Aldrich (St. Louis, MO). Dialysis tubing (6kDa MWCO) was
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purchased from Spectrum Chemical (Gardena, CA). Normal human dermal fibroblasts
(NHDF) were purchased from Lonza (Walkerville, MD) and Dulbecco’s modified Eagle
medium/Ham’s F-12 50/50 mix (DMEM/F-12) with L-glutamine, bovine growth
serum (BGS), and penicillin/streptomycin were purchased from Corning Life
Sciences (Tewksbury, MA). Alexa Fluor 594 phalloidin, Pierce Silver Stain kit, and
alamarBlue reagent were purchased from Thermo Fisher Scientific (Waltham, MA).
30% acrylamide/bis solution, sodium dodecyl sulfate (SDS), 2x Laemmli sample
buffer, Dual Color molecular weight ladder, and Mini-PROTEAN Tetra Cell were
purchased from Bio-Rad Laboratories (Hercules, CA).
5.2.2 Synthesis of GelMA
GelMA was synthesized as previously described

180,311.

Briefly, gelatin was

dissolved in phosphate buffered saline (PBS w/out Ca+2/Mg+2, pH 7.4) at 10% w/v
and stirred for 30 minutes at 50°C until fully dissolved. The stirring speed was then
increased to 600rpm and methacrylic anhydride was added at a ratio of 0.12g
methacrylic anhydride/1g gelatin. The mixture was allowed to react for 1 hour and
then split into two equal volume fractions and purified either by 1) the conventional
dialysis method or 2) acetone precipitation.
5.2.2.1 Dialysis and Lyophilization Method
Pre-warmed ultra-pure deionized water (2x volume) was added to the
gelatin/methacrylic anhydride reaction, and the solution transferred to dialysis
tubing (6kDa MWCO). The product was dialyzed against water for 7 days at 40°C and
GelMA recovered by lyophilization.
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5.2.2.2 Acetone Precipitation Method
The gelatin/methacrylic anhydride reaction mixture was precipitated in
acetone (10x volumetric excess) while stirring. GelMA was collected by vacuum
filtration using 0.45μm nylon filters and pressed down to expel any excess acetone
residing within the product. Recovered product was dried under vacuum for 30
minutes. The dried product was redissolved in ultra-pure deionized water (10% w/v)
at 50°C for 1 hour. Vacuum drying and redissolution were repeated 3-4 times, with
the final vacuum drying allowed to continue for 48 hours.
5.2.2.3 Hydrogel Polymerization
GelMA purified by dialysis and acetone precipitation was dissolved in 0.1M
PBS at 50°C. Irgacure 2959 photoinitiator (I-2959, 0.1% w/v) was added, the solution
vortexed, and briefly centrifuged in a benchtop minifuge to remove air bubbles.
Hydrogel discs (100μL) were photopolymerized between glass slides separated by
1mm Teflon spacers for 5 minutes on each side.
5.2.3 Characterization of GelMA
The chemical composition/purity, degree of functionalization, and molecular
weight of GelMA purified by dialysis and acetone precipitation methods were
analyzed by proton nuclear magnetic resonance (1H-NMR), ninhydrin assay, and
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), respectively.
Where appropriate, native (unmodified) gelatin was included for comparison.
5.2.3.1 NMR Analysis
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Gelatin and GelMA samples (2.5% w/v) were prepared in deuterium oxide
(D2O), filtered, and analyzed using a Bruker Avance 500MHz NMR spectrometer.
5.2.3.2 Degree of Functionalization Analysis
Degree of functionalization (DoF) for GelMA samples was determined by
ninhydrin assay as previously described

219.

Ninhydrin solution was prepared by

combining 0.5M sodium citrate monobasic (pH 5.5) and glycerol (ratio of 1:2) with
ninhydrin to a final ninhydrin concentration of 2.5 mg/mL. Gelatin standards (50μL,
0 to 3.5 mg/mL) and GelMA samples (50μL, 3.5 mg/mL) were mixed with ninhydrin
solution (950μL) in 2mL microcentrifuge tubes, vortexed, and placed in a 50°C water
bath for 2 hours until standards appeared purple in color. Standards and samples
were transferred (250μL) in triplicate to a 96-well plate and absorbance was
measured at 570nm with a Biotek Synergy 4 plate reader. DoF was calculated from a
gelatin standard curve as (100-X)%, where X is the percentage of the original
undiluted native gelatin standard.
5.2.3.3 SDS-PAGE Total Protein Analysis
Gelatin and GelMA samples were mixed with reducing sample buffer (1:20 2mercaptoethanol:2x Laemmli sample buffer) to a final concentration of 33.33μg/mL,
heated in water at 95°C for 10 minutes, and centrifuged at maximum speed for 20
seconds. Samples (15μL, 500ng protein) and Dual Color molecular weight ladder
(10μL) were loaded onto polyacrylamide gels (6% stacking/10% resolving) and
electrophoresed at 150V for 65 minutes. Gels were stained using a Silver Stain kit and
imaged with a ChemiDoc-It 2 Imager (UVP Imaging).
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5.2.3.4 Gel Content and Swelling
GelMA hydrogels (5% and 10% w/v) were submerged in deionized water,
kept in a -80°C freezer overnight, and lyophilized for 24 hours. Lyophilized samples
were weighed (Wd1), rehydrated in deionized water for 24 hours, and weighed again
(Ww). Rehydrated samples were frozen at -80°C overnight, lyophilized again for 24
hours, and weighed (Wd2) a final time. The gel content for each GelMA sample was
Wd2

calculated as: Gel content (%) = (

) x 100. The mass swelling ratio for each GelMA

Wd1

sample was calculated as: Mass swelling ratio (qm) =

Ww

.

Wd2

5.2.3.5 Mechanical Properties
GelMA hydrogels (150μL, 2.5%, 5%, and 10% w/v) were photopolymerized in
wells of a 96-well plate (w/well plate lid) to a final size of 3mm (height) x 7mm
(diameter). Hydrogel samples were mechanically tested by a uniaxial unconfined
compression test to determine Young’s modulus of the materials. A Bose Electroforce
3200 was outfitted with a 250g load cell and samples were subjected to a strain rate
of 25%/min over 3 minutes. Young’s modulus was calculated from load and
displacement values between 20-30% strain, with the unloaded cross-sectional area
used for stress calculations and unloaded height used as the initial value for
calculating strain.
5.2.4 Evaluation of GelMA Bioactivity
5.2.4.1 Cell Morphology
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GelMA hydrogel precursor solutions (5% w/v) were made under sterile
conditions

and

filtered

(0.45μm

filter).

Hydrogel

discs

(100μL)

were

photopolymerized, placed into a 24-well plate, and equilibrated with DMEM cell
culture medium supplemented with BGS (10% v/v) and penicillin/streptomycin (1%
v/v) for 10 minutes. NHDF were seeded (100,000 cells/mL) directly on top of each
hydrogel and cultured at 37°C for 24 hours. Cells were stained with Alexa Fluor 594
phalloidin and imaged using a Zeiss AxioVert 200 Inverted Fluorescence microscope.
Circularity was calculated (circularity = (4π*area)/(perimeter^2)) using the Analyze
Particles feature on ImageJ.
5.2.4.2 Cell Invasion
Cell invasion was evaluated using a gel-in-gel model in which NHDF
encapsulated in small fibrin clots were embedded within GelMA hydrogels. Fibrin
clots were prepared by mixing the following components (final concentrations
indicated): calcium chloride (25mM), thrombin (0.001 U/mL), fibrinogen (43.48
mg/mL), and NHDF (20,000 cells/μL) in DMEM/F-12 cell culture medium. 4μL
aliquots were quickly pipetted onto Petri dishes and incubated at 37°C for 20 minutes
before use. GelMA solutions (100μL) were pipetted onto glass slides and fibrin clots
were placed into the center before placing a second glass slide on top, separated by
1mm Teflon spacers. GelMA hydrogels containing fibrin clots were photopolymerized
for 10 minutes on one side, placed into 24-well plates containing supplemented
DMEM/F-12 cell culture medium, and cultured at 37°C for 14 days. Images of
encapsulated fibrin clots were taken at days 0, 3, 7, and 10.
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5.2.5 Cytotoxicity by Extract/Degradation Product Analysis
For extract testing, GelMA hydrogels (5% w/v) were incubated at 37°C for 24
hours in 0.5mL of supplemented DMEM cell culture medium. For degradation product
testing, hydrogels were incubated in 1N NaOH for 1 hour at 60°C until completely
degraded and neutralized with 1N HCl. The residual degradation products were
stored at -80°C overnight and lyophilized for 24 hours. Lyophilized degradation
products were reconstituted in DMEM (200μL, 100μL per 50μL hydrogel) and sterile
filtered (0.2μm PES filter). NHDF were seeded (200,000 cells/well) in 24-well plates
and cultured at 37°C for 24 hours. Cell culture medium was removed from wells and
replaced with extract solution (1:1 with DMEM), degradation product solution
(100μL per 1mL DMEM), or left untreated with fresh DMEM. All samples were
cultured in their respective conditions at 37°C for 24 hours. Cell viability was
measured using alamarBlue reagent (1/10th volume of DMEM) added to each well
and incubated at 37°C for 12 hours. Fluorescence was measured at 555nm excitation
and 590nm emission using a Biotek Synergy 4 plate reader. Cell viability for
experimental conditions was calculated as the percentage of the untreated/control
samples.
5.2.6 Statistical Analysis
Statistical comparisons were performed using one-way analysis of variance
(ANOVA). P-values less than 0.05 were considered significant. Data are expressed as
mean +/- standard deviation with significant differences marked as * (p < 0.05).
5.3 RESULTS & DISCUSSION
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5.3.1 Characterization of GelMA
5.3.1.1 Structural Analysis
GelMA was synthesized by reacting gelatin with methacrylic anhydride,
replacing amino and hydroxyl side chains of gelatin with methacrylamide and
methacrylate groups. To determine if the products of the two precipitation methods
were structurally similar, 1H-NMR was performed, and the resulting spectrograms
were compared against native gelatin (Figure 5.1A). GelMA samples displayed
similar peaks to native gelatin, verifying that both GelMA synthesis methods preserve
the structure of gelatin. Additionally, GelMA precipitated by acetone displayed
identical methacrylamide and methacrylate peaks to GelMA purified by dialysis at
5.52ppm and 5.27ppm. GelMA samples were further evaluated by SDS-PAGE (Figure
5.1B) to determine if the GelMA samples retained the native protein composition of
gelatin, as well as display identical composition between the two GelMA samples.
Staining using a Silver Stain kit revealed that all three samples, native gelatin, GelMA
(dialysis), and GelMA (acetone), showed very similar protein composition, verifying
that the main gelatin chain of both GelMA samples remained unchanged. To evaluate
the degree of functionalization (DoF), a ninhydrin assay was performed on dialyzed
and acetone precipitated GelMA samples, and compared to native gelatin standards
(Figure 5.1C). GelMA samples were fit to the linear regression line of the gelatin
standard curve and calculated for the percentage of available amines relative to the
original undiluted gelatin standard. Results of the ninhydrin assay demonstrated that
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both the dialyzed and acetone precipitated GelMA samples had DoF of ~51%, in line
with previous studies using similar ratios of MA/gelatin 181,219.

Figure 5.1. Characterization of GelMA samples were performed by 1H-NMR, SDSPAGE, and ninhydrin assay. A) NMR spectrograms for native gelatin, GelMA (dialysis),
and GelMA (acetone) Spectrograms showed congruencies between native gelatin and
GelMA samples, along with similar methacrylamide and methacrylate peaks for both
GelMA samples at 5.52ppm and 5.27ppm. B) SDS-PAGE of GelMA samples also
showed similar protein structures to native gelatin, as well as between GelMA
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samples. C) Ninhydrin assay demonstrated that both GelMA samples had a degree of
functionalization (DoF) at ~51%.

5.3.1.2 Gel Content and Swelling
Dialyzed and acetone precipitated GelMA samples were further evaluated for
congruency by swell testing photopolymerized and thermogelled hydrogels created
from each sample. Testing involved two dry weight measurements after
lyophilization and one wet weight measurement after rehydration from the first
lyophilization. Gel content and mass swelling both showed no significant difference
between either the photopolymerized or thermogelled groups (Figure 5.2). There
was, however, a slight decrease in gel content for both GelMA samples precipitated
by acetone when compared to the GelMA samples that were dialyzed. Acetone
precipitated GelMA samples were calculated at an average of 94.5% and 92.2% for
the photopolymerized and thermogelled samples, respectively, whereas the dialyzed
GelMA samples had calculated gel content of 97.8% and 97.2%. Mass swelling
calculations showed very little difference between photopolymerized GelMA
samples, while the acetone precipitated thermogelled sample group showed a slight
decrease compared to the dialyzed sample group. From these results, we can
determine that there are enough similarities between the products of the two
purification methods to move forward with further analyses.
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Figure 5.2. GelMA photopolymerized and thermogelled (T) samples evaluated by A)
gel content and B) mass welling. Photopolymerized and thermogelled samples did not
show any significant difference.

5.3.1.3 Mechanical Properties
Mechanical strength of hydrogel scaffolds has a direct correlation to the
degree of cell proliferation within the hydrogel matrix. Hydrogels with mechanical
properties that are closer to the native tissue at the implant site are more likely to
have successful interactions with adjacent and encapsulated cells. Young’s modulus
can help determine the strength of a given material and provide vital information to
how the material can be used best. Dialyzed and acetone precipitated GelMA samples
were subjected to uniaxial unconfined compression testing to determine if there were
any significant changes to the Young’s modulus with the new acetone precipitated
synthesis method. Compression testing showed that there was no difference in
mechanical strength between either precipitation method at any of the
concentrations (2.5%, 5%, 10% w/v) tested (Figure 5.3). The mechanical strength
between the different concentrations was significantly different, however, but this

99

was expected due to the higher density of crosslinking in the higher concentration
samples.

Figure 5.3. Mechanical properties of dialyzed and acetone precipitated GelMA (10%,
5%, and 2.5% w/v) were tested by uniaxial unconfined compression tests to
determine Young’s modulus. There was no significant difference between dialyzed
and acetone precipitated GelMA samples at any of the concentrations tested. Young’s
modulus was significantly different between similar samples at each concentration.
Statistical comparisons between groups are indicated as * (p < 0.01).

5.3.2 Evaluation of GelMA Bioactivity
To evaluate if acetone precipitation of GelMA would have a side effect on the
bioactivity of the material, NHDF were seeded on top of and encapsulated within
dialyzed and acetone precipitated GelMA hydrogels. Cell morphology was evaluated
by seeding NHDF on top of GelMA hydrogels and culturing for 24 hours. Cells were
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actin-stained with phalloidin and imaged with a fluorescent microscope to determine
cell morphology (Figures 5.4 and 5.5). Images revealed that there was no observable
difference between the morphology of NHDF on dialyzed and acetone precipitated
GelMA hydrogels. Circularity calculations also demonstrated that there was no
significant difference between dialyzed and acetone precipitated GelMA samples. Cell
invasion was evaluated by encapsulating NHDF within a fibrin clot and placing the
clot within the center of the hydrogel before photopolymerization. Encapsulated clots
were cultured for 10 days, and images were taken at days 0, 3, 7, and 10 (Figure 5.6).
Images showed that cell invasion was comparable between the dialyzed and acetone
precipitated groups. Measurements of longest cell projections showed no significant
difference between GelMA groups but showed a significant difference in lengths
between days 3 and 7 (Figure 5.7). There was no discernible difference in cell
morphology or cell invasion between the two GelMA groups in either experiment,
verifying that the acetone precipitation synthesis method does not impact the
bioactivity of GelMA.

Figure 5.4. Fluorescent images of actin stained NHDF on 5% w/v GelMA hydrogels
made from GelMA purified by A) dialysis and B) acetone precipitation after 24 hours
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culture (Scale bar = 200µm). C) Circularity calculations show no significant difference
in cell morphology between the two purification methods.

Figure 5.5. Fluorescent images of actin stained NHDF on 5% w/v GelMA hydrogels
made from GelMA purified by A) dialysis and B) acetone precipitation after 24 hours
culture (Scale bar = 80µm).

Figure 5.6. Encapsulated fibrin clots containing NHDF embedded within dialyzed and
acetone precipitated GelMA hydrogels (5% w/v) (Scale bar = 200µm). Encapsulated
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clots were cultured for 10 days and imaged at 0-, 3-, 7-, and 10-day time points. No
discernible difference in cell invasion was observed between the two GelMA groups.

Figure 5.7. Encapsulated fibrin clots containing NHDF embedded within dialyzed and
acetone precipitated GelMA hydrogels (5% w/v). Encapsulated clots were cultured
for 10 days, and longest cellular projections were measured at 3, 7, and 10 days.
Statistical comparisons between groups are indicated as * (p < 0.05).

5.3.3 Evaluation of GelMA Cytotoxicity
To evaluate the potential cytotoxicity of GelMA purification by acetone
precipitation, extract and degradation products were isolated from dialyzed and
acetone precipitated GelMA hydrogels and cell viability assays were performed.
NHDF were cultured with hydrogel extract, degradation products, or left untreated
for 24 hours before alamarBlue reagent was added to determine cell viability.
Comparisons between the two GelMA groups for both experimental conditions show
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no significant difference between the dialyzed and acetone precipitated samples
despite there being a slight decrease in cell viability for the acetone precipitated
GelMA hydrogel degradation product compared to dialyzed GelMA (Figure 5.8). All
samples showed cell viability above 103% of the untreated control. GelMA samples
were calculated as a percentage of the untreated control to normalize the values but
were not compared against the untreated control in terms of statistical significance.
It is clear from these assays, however, that gelatin can support cell viability even in
its modified form.

Figure 5.8. Viability of NHDF cultured with dialyzed and acetone precipitated GelMA
hydrogel extract and degradation products presented as a percentage of the
untreated control. No significant difference was observed between GelMA groups for
either experimental condition.

5.4 CONCLUSION
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GelMA synthesis methods utilizing dialysis and lyophilization purification
methods are time-consuming and can slow down the rate of research. GelMA
purification by acetone precipitation significantly reduces the overall time for
synthesis completion without sacrificing functionality of the product. Structural,
mechanical, and bioactive characterization of acetone precipitated GelMA showed no
significant deviations from the conventional dialysis methods, verifying the efficacy
of the product. These studies show that acetone precipitation can serve as a functional
alternative to dialysis and lyophilization in the synthesis of GelMA, reducing the time
for synthesis completion and potentially increasing productivity of investigators
employing this method.
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CHAPTER SIX
AIM IV: SYNTHESIS AND CHARACTERIZATION OF POLY(ETHYLENE GLYCOL)
DIACRYLATE/GELATIN METHACRYLATE/GLYCIDYL METHACRYLATE
HYALURONIC ACID HYBRID HYDROGELS

6.1 INTRODUCTION
Hydrogels have been extensively studied for therapeutic use in delivery of genes,
cells, and bioactive molecules. To be effective, hydrogel scaffolds for delivery of
therapeutic agents need to have several key functions. First, mechanical properties of
scaffolds need to promote cell adhesion, proliferation, migration, and survival in 3D
87.

Second, they need to provide bioactive properties for facilitating site-specific

release of the therapeutic agent

319.

Third, degradation of the scaffold needs to

support regeneration of the surrounding tissue, as well as regulate release of the
therapeutic agent in delivering a local, sustained dosage and prevent systemic side
effects 164. Developing a hydrogel delivery system with these functions is an effective
way to protect therapeutic agents from degradation and preserve the bioactivity
within the immediate environment.
The composition of a hydrogel plays a significant role in the application of the
scaffold, with many composed entirely from polymeric materials, including
poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), poly[N-(2-hydroxypropyl)
methacrylamide] (PolyHEMA), alginate, agarose, hyaluronic acid (HA), collagen, and
gelatin, among others

320–326.

With the unique ability of polymers to be chemically
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modified, polymeric hydrogels provide a convenient and minimally invasive method
of delivering therapeutic agents to target sites 327. Many hydrogel formulations have
been optimized to mimic the viscoelastic properties of soft tissues to better suit the
environment for implantation and function 328. Using naturally derived polymers as
hydrogel components provides support for cellular processes, like cell adhesion,
proliferation, migration, and survival, but lack the necessary mechanical properties
for stability within a physiological environment 128,225,226. Synthetic polymers, on the
other hand, provide superior mechanical properties that can easily be tuned for
specific applications, but do not innately offer bioactive support 97,100,204.
Recent studies have utilized natural and synthetic polymers in combination to
form tunable hybrid hydrogel systems, taking advantage of the unique properties
both types of polymers display 178,311,329. Previous work in the lab has demonstrated
the advantages of using a hybrid hydrogel, crosslinking PEG diacrylate (PEGdA) with
entrapped native HA in a semi-interpenetrating network (semi-IPN) 179. PEGdA/HA
semi-IPNs possess unique qualities that support cell migration stemming from
blended PEGdA macromers and partial phase separation of HA within the network.
Cell-mediated degradation of the hydrogel matrix allows for increased cell spreading
in the dynamic microenvironment and supports cell survival in 3D. When compared
to hydrogels consisting of modified methacrylated hyaluronic acid (GMHA) in place
of native HA, there was a lack of support for cell spreading on the surface of the
scaffolds. By chemically modifying the polymeric components with acrylate and
methacrylate groups, highly structured copolymer microenvironments can be
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created, reducing the chance of phase separation to occur. Modified methacrylated
gelatin (GelMA) is a versatile material, recently drawing significant attention from
research groups in 3D bioprinting for creating cell- and drug-loaded scaffolds
317,330,331.

Native gelatin contains RGD sequences that are essential for cell adhesion

and spreading, a glaring challenge in the previously mentioned PEGdA/GMHA
copolymer hydrogels. In the following studies, we describe the polymerization of
various PEGdA/GelMA/GMHA copolymer hydrogel formulations and test the
mechanical and bioactive properties against PEGdA/HA semi-IPN hydrogels.
6.2 MATERIALS AND METHODS
6.2.1 Materials
Gelatin

from

porcine

skin

(Type

A),

methacrylic

anhydride,

2-

mercaptoethanol, acetone, carbonyldiimidazole (CDI), triethylamine (TEA), sodium
acrylate, 2-chloropropionyl chloride, chloroacetyl chloride, 4-chlorobuturyl chloride,
glycidyl methacrylate, dimethylsulfoxide (DMSO), dimethylformamide (DMF),
dichloromethane (DCM), ethyl ether, chloroform, ninhydrin, sodium citrate
monobasic, glycerol, and 4-methoxyphenol were purchased from Sigma-Aldrich (St.
Louis, MO). Hyaluronic acid (HA, sodium salt, MW 1.5MDa) and PEG diol (4kDa) were
purchased from LifeCore Biomedical (Chaska, MN) and Fluka (Buchs, Switzerland),
respectively.

Carbonyldiimidazole

bromide

(TBA-Br)

and

Dowex

50WX8

200−400(H) were purchased from Alfa Aesar (Ward Hill, MA). Alexa Fluor 594
phalloidin and alamarBlue reagent were purchased from Thermo Fisher Scientific
(Waltham, MA). Normal human dermal fibroblasts (NHDF) were purchased from

108

Lonza (Walkersville, MD). Dulbecco’s modified Eagle medium/Ham’s F-12 50/50 mix
(DMEM/F-12)

with

L-glutamine,

bovine

growth

serum

(BGS),

and

penicillin/streptomycin were purchased from Corning Life Sciences (Tewksbury,
MA).
6.2.2 Polymer Synthesis
6.2.2.1 PEGdA Macromer Synthesis
Polyethylene glycol diacrylate (PEGdA) derivatives, PEG-bis-(acryloyloxy
acetate) (PEG-bis-AA), PEG-bis-(acryloyloxy propanoate) (PEG-bis-AP), and PEG-bis(acryloyloxy butyrate) (PEG-bis-AB), were synthesized by a two-step reaction as
previously described

209.

PEG hydroxyl groups were reacted with chloroacetyl

acetate, 2-chloropropionyl chloride, or 4-chlorobuturyl chloride to form PEG-bis(chloroacetate),

PEG-bis-(2-chloropropanoate),

or

PEG-bis-(4-chlorobutyrate)

respectively. Intermediate products were reacted with sodium acrylate and dried to
obtain PEG-bis-AA, PEG-bis-AP, and PEG-bis-AB powders. The structure and degree
of acrylation of the final products were determined by 1H NMR (CDCl3-d3) as
previously described 209.
6.2.2.2 GelMA Synthesis
Gelatin methacrylate (GelMA) was synthesized as previously described
(original reference) and purified using the new acetone precipitation method
described in Chapter 5. Type A gelatin from porcine skin (10% w/v) was dissolved in
phosphate buffered saline (PBS w/out Ca+2/Mg+2, pH 7.4) and stirred for 30 minutes
at 50°C until fully dissolved. After dissolution, stirring speed was increased to
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600rpm and methacrylic anhydride was added based on the functionalization of
1.12g methacrylic anhydride/1g gelatin. The mixture was allowed 1 hour to react.
The gelatin/methacrylic anhydride reaction product was precipitated in acetone (10x
volumetric excess) while stirring. GelMA was collected by vacuum filtration using
0.45μm nylon filters and pressed down to expel any excess acetone residing within
the product. Recovered product was dried under vacuum for 30 minutes. The dried
product was redissolved in ultra-pure deionized water (10% w/v) and stirred at 50°C
for 1 hour. Vacuum drying and redissolution were repeated 3-4 times, with the final
vacuum drying allowed to continue for 48 hours. Degree of functionalization was
determined by ninhydrin assay as previously described 181,219.
6.2.2.3 GMHA Synthesis
Methacrylated HA (GMHA) was synthesized by reacting sodium hyaluronate
(HA) with glycidyl methacrylate as previously described 332. HA (1g) was dissolved in
ultra-purified water (100mL) overnight and stirred at 300rpm. TEA (8.796mL) was
added to the dissolved HA and stirred for 3 hours in the dark. Glycidyl methacrylate
(GM) was then added at an excess of 20x molar concentration and allowed to react
for 4 hours in the dark. The reaction was heated with constant stirring for 1 hour at
60°C and then cooled down in the dark. The cooled down reaction solution was
precipitated in acetone (10x volumetric excess) and vacuum filtered with a 0.45μm
nylon filter. Precipitated GMHA was redissolved in ultra-pure water for 3 hours then
precipitated and filtered two more times. The final redissolution was dialyzed (12-
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14kDa MWCO) against water for 72 hours and lyophilized for an additional 72 hours
to recover the final GMHA product.
6.2.2.4 Hydrogel Polymerization
Blended PEGdA (12.5% PEG-bis-AA, 37.5% PEG-bis-AP, and 50.0% PEG-bisAB), GelMA, and GMHA were mixed in various concentrations to form hydrogel
precursor solutions (Table 6.1). An additional hydrogel precursor solution was made
using blended PEGdA (6% w/v) and native HA (0.36% w/v) and supplemented with
RGD peptide (10% v/v) as previously described 179. Precursor solutions were mixed
with

2-hydroxy-1-[4-(hydroxyethoxy)phenyl]-2-methyl-1-propanone/Irgacure

2959 photoinitiator (I-2959, 0.1% w/v) by vortexing. Hydrogel discs (100μL) were
photopolymerized between glass slides separated by 1mm Teflon spacers for 5
minutes on each side.

Table 6.1. Composition of hybrid hydrogels containing various concentrations (0.36,
0.5, 1, 2, 4, and 6% w/v) of blended PEGdA (P), GelMA (G), HA (H), and GMHA.
Sample
2G/6P
2G/4P
2G/2P
4G/1P
2G/1P
1G/1P
0.5G/1P
6P/0.36H

PEGdA (Final %)
6%
4%
2%
1%
1%
1%
1%
6%

GelMA (Final %)
2%
2%
2%
4%
2%
1%
0.5%

GMHA/(HA) (Final %)
1%
1%
1%
1%
1%
1%
1%
(0.36%)

6.2.3 Characterization of PEGdA/GelMA/GMHA Hydrogel
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6.2.3.1 Gel Content and Swelling
PEGdA/GelMA/GMHA and PEGdA/HA hydrogels (100μL discs) were
submerged in deionized water, kept in at -80°C overnight, and lyophilized for 24
hours using a Labconco FreeZone 12L Freeze Dry System. Lyophilized samples were
weighed (Wd1), rehydrated in deionized water for 24 hours, and weighed again (Ww).
Rehydrated samples were frozen at -80°C overnight, lyophilized again for 24 hours,
and weighed (Wd2) a final time. The gel content for each hydrogel sample was
calculated as: Gel content (%) = (

Wd2

) x 100. The mass swelling ratio for each

Wd1

hydrogel sample was calculated as: Mass swelling ratio (qm) =

Ww

.

Wd2

6.2.3.2 Turbidity Analysis
Hydrogel samples (100μL) were photopolymerized for 10 minutes directly in
wells of a 96-well plate. Absorbance was measured for photopolymerized hydrogels
at 570nm using a Biotek Synergy 4 plate reader. Turbidity, a measure of phase
separation, was calculated as T = -ln(10-A), where A is the measured absorbance.
6.2.3.3 Mechanical Properties
Hydrogels (150μL) were photopolymerized in wells of a 96-well plate as
described above to a final size of 3mm (height) x 7mm (diameter). Hydrogel samples
were mechanically tested by a uniaxial unconfined compression test to determine
Young’s modulus of the materials. A Bose Electroforce 3200 was outfitted with a 250g
load cell and samples were subjected to a strain rate of 25%/min over 3 minutes.
Young’s modulus was calculated from load and displacement values between 20-30%
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strain, with the unloaded cross-sectional area used for stress calculations and
unloaded height used as the initial value for calculating strain.
6.2.4 Evaluation of PEGdA/GelMA/GMHA Hydrogel Bioactivity
6.2.4.1 Cell Morphology
PEGdA/GelMA/GMHA and PEGdA/HA hydrogel precursor solutions were
made under sterile conditions and filtered (0.45μm filter). Hydrogel discs (100μL)
were photopolymerized, placed into a 24-well plate, and equilibrated with DMEM cell
culture medium supplemented with BGS (10% v/v) and penicillin/streptomycin (1%
v/v) for 10 minutes. NHDF were seeded (100,000 cells/mL) directly on top of each
hydrogel and cultured at 37°C for 24 hours. Cells were stained with Alexa Fluor 594
phalloidin and imaged using a Zeiss AxioVert 200 Inverted Fluorescence microscope.
6.2.4.2 Cell Invasion
PEGdA/GelMA/GMHA and PEGdA/HA solutions were made under sterile
conditions as previously mentioned. Hydrogel precursor solutions (100μL) were
pipetted onto glass slides and fibrin clots were placed into the center before placing
a second glass slide on top, separated by 1mm Teflon spacers. Fibrin clot solutions
were made by combining calcium chloride (25mM final), thrombin (0.001 U/mL
final), and DMEM cell culture medium (7% final) and kept on ice for 5 minutes before
combining with fibrinogen (43.48 mg/mL final) and NHDF cells (20,000 cells/μL,
50% final volume). Fibrin clot solutions (4μL) were quickly pipetted onto petri dishes
and incubated at 37°C for 20 minutes before use. GelMA hydrogels with encapsulated
fibrin clots were photopolymerized for 10 minutes on one side, placed into 24-well
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plates containing supplemented DMEM cell culture medium, and cultured at 37°C for
14 days. Phase-contrast images of encapsulated fibrin clots were taken at days 0, 3, 7,
and 14, and compared for cell migration.
6.2.5 Statistical Analysis
Statistical comparisons were performed using one-way analysis of variance
(ANOVA). P-values less than 0.05 were considered significant. Data are expressed as
mean +/- standard deviation with significant differences marked as * (p < 0.05).
6.3 RESULTS
6.3.1 Characterization of PEGdA/GelMA/GMHA Hydrogels
6.3.1.1 Gel Content and Swelling
Gel content for samples 2G/6P, 2G/4P, 2G/2P, and 4G/1P were not
significantly different from the 6P/0.36H control samples at 92.1% (Figure 6.1A).
Samples containing lesser concentrations of polymer, 2G/1P, 1G/1P, and 0.5G/1P,
were all significantly less than 6P/0.36H, with gel content at 84.6%, 74.9%, and
66.5%, respectively. Between PEGdA/GelMA/GMHA groups, only 2G/6P and 2G/4P,
2G/4P and 2G/2P, 2G/6P and 4G/1P, 2G/4P and 4G/1P, and 2G/2P and 4G/1P
samples were not significantly different.
Swelling of the hydrogel samples was calculated as a mass swelling ratio
between

the

equilibrium

wet

weight

and

the

final

dried

weight.

PEGdA/GelMA/GMHA samples 2G/4P, 2G/2P, 2G/1P, 1G/1P, and 0.5G/1P were all
significantly different from the 6P/0.36H control sample at 13.9, with 2G/6P being
the only sample significantly less than the control (Figure 6.1B). 2G/4P and 4G/1P
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were the only samples not significantly different from 6P/0.36H at 14.6 and 15.5,
respectively.

Figure 6.1. A) Gel content and B) mass swelling ratio of experimental
PEGdA/GelMA/GMHA hydrogels and control PEGdA/HA hydrogels based on dry
weight after photopolymerization (Wd1), rehydrated wet weight (Ww), and dry weight
after rehydration (Wd2). Statistical comparisons between PEGdA/HA and individual
PEGdA/GelMA/GMHA groups are indicated as * and comparisons between
PEGdA/GelMA/GMHA groups are indicated as # (p < 0.05).

6.3.1.2 Turbidity and Mechanical Properties
Turbidity for the PEGdA/GelMA/GMHA hydrogels were all significantly less
than the 6P/0.36H control hydrogel, except for the 2G/6P formulation, which showed
no

significant

difference

(Figure

6.2).

Mechanical

properties

for

PEGdA/GelMA/GMHA copolymer samples 2G/6P, 2G/4P, 4G/1P, 1G/1P, and 0.5G/1P
were all significantly different from the PEGdA/HA semi-IPN control, with 2G/2P and
2G/1P being the only samples not significantly different from the control (Figure
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6.3). Between PEGdA/GelMA/GMHA groups, only 2G/6P and 4G/1P, and 2G/4P and
4G/1P were not significantly different from each other.

Figure 6.2. Turbidity analysis of photopolymerized PEGdA/GelMA/GMHA and
PEGdA/HA hydrogels. Hydrogel samples were photopolymerized directly in 96-well
plates and turbidity was measured using absorbance (A) at 570nm and calculated as
T=-ln(10-A). Statistical comparisons between PEGdA/HA and PEGdA/GelMA/GMHA
groups are indicated as * (p < 0.01).
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Figure 6.3. Young’s modulus of PEGdA/GelMA/GMHA copolymer hydrogels
calculated from uniaxial unconfined compression testing. Young’s modulus was
calculated from load and displacement values between 20-30% strain, with the
unloaded cross-sectional area used for stress calculations and unloaded height used
as the initial value for calculating strain. Statistical comparisons between PEGdA/HA
and individual PEGdA/GelMA/GMHA groups are indicated as * and comparisons
between PEGdA/GelMA/GMHA groups are indicated as # (p < 0.05).

6.3.2 Evaluation of PEGdA/GelMA/GMHA Hydrogel Bioactivity
6.3.2.1 Cell Morphology
Actin-stained NHDF cultured on PEGdA/GelMA/GMHA copolymer hydrogels
showed promising results in cell adhesion and spreading after 24 hours. Fluorescent
images (4x magnification) of NHDF on copolymer hydrogels showed consistent cell
spreading relative to the concentration of GelMA (Figure 6.4). Additional images
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(10x magnification) reveal the actin cytoskeletal organization of NHDF on each of the
hydrogel formulations (Figure 6.5). Compared to PEGdA/HA semi-IPNs, cell
spreading on copolymer samples 2G/6P, 2G/4P, 2G/2P, 4G/1P, and 2G/1P all
demonstrated significantly increased spreading/reduced circularity, while 0.5G/1P
had significantly increased circularity (Figure 6.6). Copolymer sample 1G/1P
showed comparable circularity to the PEGdA/HA semi-IPN sample.

Figure 6.4. Morphology of actin stained NHDF on A) 2G/6P, B) 2G/4P, C) 2G/2P, D)
4G/1P, E) 2G/1P, F) 1G/1P, G) 0.5G/1P PEGdA/GelMA/GMHA copolymer and H)
6P/0.36H PEGdA/HA semi-IPN hydrogels after 24 hours in culture (Scale bar =
200µm).

118

Figure 6.5. Morphology of actin stained NHDF on A) 2G/6P, B) 2G/4P, C) 2G/2P, D)
4G/1P, E) 2G/1P, F) 1G/1P, G) 0.5G/1P PEGdA/GelMA/GMHA copolymer and H)
6P/0.36H PEGdA/HA semi-IPN hydrogels after 24 hours in culture (Scale bar =
80µm).

Figure 6.6. Circularity of NHDF seeded on PEGdA/GelMA/GMAH copolymer and
PEGdA/HA semi-IPN hydrogels after 24 hours in culture. Statistical comparisons
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between PEGdA/HA and individual PEGdA/GelMA/GMHA groups are indicated as *
and comparisons between PEGdA/GelMA/GMHA groups are indicated as # (p < 0.05).

6.3.2.2 Cell Invasion
Migration of NHDF from encapsulated fibrin clots varied across the different
PEGdA/GelMA/GMHA copolymer formulations at day 3 (Figure 6.7). Hydrogels with
significantly higher and lower Young’s moduli than PEGdA/HA semi-IPN hydrogels
demonstrated a lack of support for migration. PEGdA/GelMA/GMHA sample, 4G/1P,
was the lone exception as it had a significantly higher Young’s modulus but supported
comparable cell migration to the semi-IPN control. The addition of GelMA appeared
to have some impact on the bioactivity of the hydrogel, also seen in the cell
morphology study. By day 7, cells in PEGdA/GelMA/GMHA samples, 2G/4P, 2G/2P,
4G/1P, and 2G/1P, all showed improved cell migration when compared to the
PEGdA/HA semi-IPN sample. Cell invasion at day 14 was comparable between 2G/6P
and PEGdA/HA, while 2G/4P, 2G/2P, 4G/1P, and 2G/1P continued to demonstrate
improved cell migration. Assessment of the longest projections in each hydrogel
formulation showed a consistent trend of 2G/2P having the most migration at each
time point (Figure 6.8). Copolymer formulations 2G/4P, 2G/2P, 4G/1P, and 2G/1P
each showed significantly longer projections than 6P/0.36H semi-IPN at days 3 and
7, but only 2G/2P and 4G/1P were significantly longer by day 14. Formulations
0.5G/1P and 1G/1P were significantly shorter than 6P/0.36H at days 3 and 14,
respectively.
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Figure 6.7. Invasion of NHDF from encapsulated 1% w/v fibrin clots into
PEGdA/GelMA/GMHA copolymer and PEGdA/HA semi-IPN hydrogels. Images were
taken using a Zeiss AxioVert 200 microscope after 0, 3, 7, and 14 days in culture, as
labeled (Scale bar = 200µm).

Figure 6.8. Comparison of longest projections from NHDF encapsulated within 1%
fibrin clots and embedded in PEGdA/GelMA/GMHA copolymer and PEGdA/HA semiIPN hydrogels at 3, 7, and 14 days. Statistical comparisons between PEGdA/HA and
individual PEGdA/GelMA/GMHA groups are indicated as * (p < 0.05).

6.4 DISCUSSION
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The goal of this study was to develop a bioactive hybrid hydrogel system that
builds upon previous hybrid hydrogel formulations and could be used for delivery of
small molecules and regenerative medicine applications. Previous formulations used
in our lab have consisted of blended PEGdA macromers crosslinked with various
concentrations of HA. PEGdA/HA semi-IPN hydrogels have demonstrated support for
cell survival, spreading, and sustained migration, while providing unique bioactive
properties through small pockets of phase separated HA. By crosslinking blended
PEGdA, GelMA, and GMHA, bioactivity can be enhanced by utilizing a greater amount
of naturally derived polymers that support cell attachment, proliferation, and
survival. Various concentrations of PEGdA and GelMA were tested to determine if
bioactivity is limited or enhanced by the degree of polymerization or composition of
the hydrogel matrix.
6.4.1 Characterization of PEGdA/GelMA/GMHA Hydrogels
6.4.1.1 Gel Content and Swelling
PEGdA/GelMA/GMHA and PEGdA/HA hydrogels were first evaluated by swell
testing to determine their gel content and swelling behavior. Hydrogel samples were
lyophilized and rehydrated to obtain dry and wet weights used for calculations of gel
content, equilibrium water content, and mass swelling ratio. 6% w/v blended
PEGdA/0.36% w/v HA was chosen as the control formulation due to its superior
bioactive properties in previous studies in the lab performed against other hydrogel
compositions. In terms of gelation, as total polymer concentration decreased, gel
content also decreased for the tested hydrogels. These results demonstrate that gel
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content directly correlated to the total concentration of polymer within the gel
matrix, as there are fewer monomers available for crosslinking. In terms of swelling,
it was observed that the lower polymer concentration samples were noticeably larger
or more swollen than the highest polymer concentration samples. This observation is
corroborated by the experimental calculations shown in Figure 6.1 above and
supports the idea that a less concentrated or crosslinked hydrogel matrix can absorb
greater volumes of water relative to hydrogels consisting of higher monomer
concentrations. From the gel content and mass swelling calculations, the
PEGdA/GelMA/GMHA experimental samples most like the 6P/0.36H control are
2G/6P, 2G/4P, and to some extent, 2G/2P. These samples were considered early
candidates for potential continued use as a 6P/0.36H substitute prior to bioactivity
studies.
6.4.1.2 Turbidity and Mechanical Properties
The physicochemical properties of PEGdA/GelMA/GMHA hydrogels were first
evaluated by a turbidity analysis of photopolymerized samples. Turbidity has been
used in hydrogel analyses as a measure of phase separation between individual
components. Higher turbidity in hydrogels is the result of a lack of complete
polymerization between polymeric components, while lower turbidity or no turbidity
is a sign of complete polymerization. Previously in the lab, hydrogels consisting of
PEGdA/HA semi-IPNs displayed higher turbidity than those consisting of
PEGdA/GMHA copolymers, leading to small pockets of HA that were advantageous
for cell spreading and survival. Turbidity can also give insight into how a particular
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hydrogel formulation may function mechanically, in terms of strength and
degradation, as higher turbidity can lead to weaker hydrogels and faster degradation.
The focus of these experiments was two-fold: 1) does the concentration of the three
polymeric components affect the turbidity and strength of the photopolymerized
copolymer hydrogel and 2) how would these new formulations compare against the
previously tested PEGdA/HA semi-IPN.
The turbidity results demonstrate that PEGdA/GelMA/GMHA copolymer
formulations can crosslink to a greater degree between the three components when
compared against the PEGdA/HA semi-IPN. The addition of methacrylate and acrylate
groups onto the copolymer hydrogel components allows for highly organized
crosslinking and reduces the chances of any phase separation, as confirmed by the
results shown below. Higher polymer concentrations in the copolymer formulations,
however, showed slightly higher turbidity than the samples containing less polymer,
with the highest polymer concentration resulting in dramatically increased turbidity
similar to the PEGdA/HA semi-IPN. It is well known that PEG and proteins do not mix
well, and part of this study was to determine if there is a miscibility limit between the
PEG and protein components. This might be an indication that there is a limit or
saturation point to the degree of crosslinking that can occur within these hydrogels
that causes higher phase separation. Based on findings from this study, we
determined that the limit of compatibility is between 4% and 6% w/v PEG with 2%
GelMA.
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In this case, the turbidity of the PEGdA/GelMA/GMHA copolymer samples was
not an indicator of the mechanical properties as the samples containing greater
concentrations of polymer exhibited higher Young’s moduli, as well as higher
turbidity. A greater degree of crosslinking occurs within hydrogels containing higher
functionalized polymer concentrations. This increase in crosslinking is what gives
hydrogels a more rigid and organized structure, resulting in stiffer products. The
PEGdA/HA semi-IPN control samples used in this study predominantly contained
blended PEGdA (6% w/v), the only modified component for crosslinking in that
system. Without another modified component, the Young’s modulus stays relative
low at ~11kPa. Higher PEGdA and GelMA concentrations lead to stiffer hydrogels, as
evidenced by the increase in Young’s modulus with increasing PEGdA and GelMA
concentrations in the copolymer samples. Mechanical properties play a significant
role in cell behavior within a hydrogel, including cell migration and spreading. Being
able to replicate the strength, stiffness, and other mechanical properties of native
ECM would optimize the aforementioned behaviors of cells interacting with the
hydrogels. This is a major challenge, as we cannot fully replicate ECM with the tools
that are currently available. These studies, however, further demonstrate the
capabilities of modified polymer hydrogel systems and the advances in tunability that
have been made over the years.
6.4.2 Evaluation of PEGdA/GelMA/GMHA Hydrogel Bioactivity
6.4.2.1 Cell Morphology
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Biomaterials are chosen on their biocompatibility and ability to provide
support for cell adhesion, spreading, and survival. Previous work in the lab has shown
that PEGdA/GMHA copolymer hydrogels do not support cell spreading as effectively
as PEGdA/HA semi-IPNs

179.

By covalently crosslinking GelMA into the copolymer

system, we aim to alleviate the issue of decreased cell spreading. Gelatin possesses
the RGD sequences necessary for facilitating cell adhesion and spreading, and can be
easily modified with methacrylate groups, making it a suitable candidate for the
copolymer system. The goal of this morphology study was to determine the impact of
GelMA cell spreading on PEGdA/GelMA/GMHA copolymer hydrogels and quantify if
any of the formulations possess comparable properties to the PEGdA/HA semi-IPN.
The addition of GelMA into the copolymer hydrogel formulation had a
significant impact on cell morphology, as gelatin possesses the necessary RGD
sequence for cell adhesion that would otherwise need to be added to the hydrogel.
The RGD sequence is an adhesive peptide containing arginine-glycine-aspartate
(RGD) amino acids that has been exhaustively studied in cell attachment to
biomaterials. By covalently crosslinkning GelMA into the hydrogel, RGD-based cell
binding sites are evenly spread throughout the polymerized hydrogel and become an
integrated part of the gel matrix, rather than an added supplement, providing more
consistent cell attachment and spreading across the material. PEGdA/HA semi-IPNs
do not inherently contain RGD and need to be supplemented to support cell adhesion,
whereas PEGdA/GelMA/GMHA copolymer hydrogels innately contain RGD, resulting
in better support for cell adhesion and spreading. Cell morphology studies presented
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here demonstrate the advantages that GelMA provides to the copolymer formulation
when compared against the PEGdA/HA semi-IPN.
6.4.2.2 Cell Invasion
Previous work in the lab demonstrated that 6% w/v blended PEGdA/0.36%
w/v HA semi-IPN hydrogels could support cell migration and survival from
encapsulated fibrin clots up to 21 days, while 6% w/v blended PEGdA/0.36% w/v
GMHA copolymer hydrogels did not allow for much migration out of the encapsulated
fibrin clot 179. Migration from the semi-IPN hydrogels was supported by cell-mediated
degradation of phase separated HA within the gel matrix. Bioactivity of
PEGdA/GelMA/GMHA copolymer hydrogels was evaluated by pre-encapsulating
NHDF within fibrin clots that were then embedded within PEGdA/GelMA/GMHA
copolymer and PEGdA/HA semi-IPN hydrogels, as demonstrated previously. Total
migration of cells was observed over 14 days in culture.
Gelatin and hyaluronic acid are natural polymers that have demonstrated
support for cell adhesion and proliferation as biomaterial scaffolds. Modification of
these polymers with methacrylate groups allows for a more efficiently crosslinked
and rigid hydrogel structure than if the polymers were unmodified. Structurally rigid
hydrogels have been documented as poor scaffolds for cell migration due to larger
mechanical forces being applied to the cells. Previous studies in our lab showed that
PEGdA/GMHA copolymer hydrogels have inferior bioactive properties to PEGdA/HA
semi-IPN hydrogels, due to cells interacting with the minorly phase separated HA in
the semi-IPN 179. Despite the higher Young’s modulus previously reported for several
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of the PEGdA/GelMA/GMHA copolymer formulations, we were curious what the
impact of incorporating GelMA into the hydrogel system would yield. Cell invasion
studies presented here demonstrate increased support for cell migration in some of
the PEGdA/GelMA/GMHA copolymer formulations compared against the PEGdA/HA
semi-IPN. The addition of modified gelatin allows for more effective cell-mediated
proteolytic degradation of the hydrogel matrix, creating a porous, bioactive structure
capable of supporting enhanced cell migration and survival. It is clear, based on the
cell invasion study, that the 2G/2P formulation is the best candidate moving forward
as a cell-based scaffold for additional studies/models.
6.5 CONCLUSION
PEGdA/GelMA/GMHA copolymer hydrogels were synthesized as a potential
alternative to the established PEGdA/HA semi-IPN hydrogels previously used in the
lab. Characterization of the new hydrogel formulations revealed that increasing the
PEGdA or GelMA concentration subsequently increases mechanical strength and
decreases mass swelling of the polymerized hydrogels. Further evaluation of
bioactivity demonstrated the impact of incorporating GelMA into the hydrogel system
as compared to previous PEGdA/GMHA formulations. GelMA appears to solve an
issue regarding cell adhesion to PEGdA/GMHA hydrogels, as increasing GelMA
concentration led to increased cell spreading on the surface of hydrogels. Cell
invasion studies of NHDF-laden encapsulated fibrin clots showed increased cell
migration and gel matrix remodeling for samples containing 4%-6% w/v combined
PEGdA and GelMA. The results of the studies presented in this aim demonstrate that
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a PEGdA/GelMA/GMHA copolymer hydrogel improves upon the bioactivity of the
PEGdA/HA semi-IPN hydrogel at comparable polymer concentrations.
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CHAPTER SEVEN
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK

7.1 CONCLUSIONS
The overall goal of this dissertation was to develop a novel pro-angiogenic
macromolecular prodrug conjugate that could be effectively released from within a
hybrid hydrogel delivery system by cell-mediated actions for the treatment of
ischemic injuries by therapeutic angiogenesis. Every year in the US, over $300 billion
is spent on treatment of ischemic injuries, affecting nearly 50% of all adults and
making up ~30% of all deaths 333,334. Current approaches for stimulating therapeutic
angiogenesis utilize growth factors and gene therapy to deliver specific proteins in
the hope that it will stimulate the increased expression of the other angiogenic target
genes, either by direct delivery or loaded into a biocompatible delivery system. Issues
with under- or overdosing from degradation or premature clearance limit these
methods from stimulating stable, mature microvessel production without faltering of
the basement membrane.
The present studies demonstrate the ability to effectively stabilize HIF-1α by
using NOG to competitively antagonize 2-OG for its binding site, allowing HIF-1α to
translocate to the nucleus, begin transcribing for pro-angiogenic targets, and create
new microvessels for the transport of growth factors and nutrients to an injury site.
Expression of target genes, like VEGF, GLUT1, and PHD2, all increased with exposure
to released NOG, similar to natural hypoxia, and proved that dosage plays an
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important role in the level of expression of each target. Despite HIF-1α being linked
to collagen production, there were no significant changes to hydroxyproline content
or cell viability, presumably due to the low concentration of NOG needed for
angiogenic stimulation. We also demonstrated the versatility of our HA-based
conjugation method and the potential for interchanging therapeutics depending on
the injury, as DX and NOG were both successfully delivered locally and showed
sustained release from hydrogels.
Additionally, we acknowledged the importance of the delivery system used in
an application like this and developed a bilayer system using a previous PEGdA/HA
formulation to better control release, as well as developed a more bioactive hybrid
hydrogel containing higher concentrations of naturally derived polymers relative to
previous formulations used in our lab. Observations of cell behavior, i.e., adhesion and
migration, revealed the effects of using polymers containing native ECM peptide
sequences, like RGD, necessary for improved cell-material interface interactions. The
drug delivery systems synthesized in these studies demonstrated a significant step
forward in creating a safe and effective therapeutic angiogenic treatment option for
ischemic injuries, in addition to verifying the limitless potential for an easily
interchangeable macromolecular prodrug conjugate.
7.2 RECOMMENDATIONS FOR FUTURE WORK
Our novel PEGdA/GelMA/GMHA hybrid hydrogel showed improved bioactive
properties when compared against the PEGdA/HA semi-IPN. This new formulation
can be implemented in the HA-NOG drug release studies to assess the rate of NOG
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release with the improved bioactivity. Because of the differences in polymer
interactions between the copolymer and semi-IPN hydrogels, the degradation profile
could change, possibly resulting in altered release kinetics, as well. The novel
formulations could then be further evaluated for HIF-1α accumulation and target
gene expression due to NOG release, as outlined in Chapter 4.
The bilayer hybrid hydrogel used in the aforementioned studies has been
successful in sustaining local delivery of the pro-angiogenic small molecule, NOG, in
vitro with subsequent increase in HIF-1α target genes. This drug delivery system has
potential efficacy in the treatment of ischemic injury in the central nervous system
(CNS). The CNS is particularly sensitive to ischemia, as the brain receives 20% of
blood flow, despite only constituting 2% of body mass

335.

There is growing

recognition of the importance of post-injury ischemia in secondary injury
progression following spinal cord injury (SCI) and traumatic brain injury (TBI) 336,337.
Small molecule delivery for therapeutic angiogenesis has shown promise in
the treatment of ischemia from CNS injuries, with DMOG and tilorone delivery both
showing an increase in HIF-1α accumulation and pro-angiogenic gene expression
through daily administration in SCI animal models

85,200.

DMOG has also been

evaluated as a neuroprotective small molecule in traumatic brain injury and cerebral
ischemia, which infers the ability of NOG to act as a neuroprotective small molecule,
as well 257,338. These studies give us confidence that NOG could not only work as a proangiogenic small molecule for therapeutic angiogenesis in ischemic injury, but that it
could also aid the survival of neuronal cell types if applied to CNS-based ischemic
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injury. A controlled cortical impact (CCI) TBI model would be a suitable injury model
to assess both angiogenesis and neuroprotection in ischemic injury. A full outline of
experimental studies for this application can be found in Appendix A.
Additionally, previous work studying the anti-inflammatory effects of released
dexamethasone (DXM) from a HA-DXM conjugate demonstrated the efficacy of DXM
to reduce inflammation in a rat controlled cortical impact (CCI) TBI model

215.

One

major challenge with successful treatment of ischemic injury is reducing the
prolonged inflammatory response that can exacerbate the injury

339–341.

Creating a

drug delivery system utilizing both HA-NOG and HA-DXM could enhance the
regenerative capabilities of the damaged tissue. The pro-angiogenic, neuroprotective,
and anti-inflammatory combinatorial effects of NOG and DXM would be expected to
provide increased support for cell survival and regeneration by further reducing the
chances of prolonged ischemia that can lead to reperfusion injury.
As alluded to earlier, this biomolecule-conjugate drug delivery system can be
utilized in many applications, including other CNS, cardiovascular, and orthopedic
regenerative medicine. Additionally, by simply replacing the conjugated small
molecule, the library of targeted pathologies could be expanded, as well.
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APPENDICES
Appendix A

Evaluate the effect of PEGdA/HA-NOG bilayer hybrid hydrogel discs on
angiogenesis, neuroprotection, and functional recovery in a rat moderate TBI
model
SubAim 1: Assess the effect of PEGdA/HA-NOG bilayer hybrid hydrogel discs on HIF1α regulated gene expression and angiogenesis
SubAim 2: Assess the effect of PEGdA/HA-NOG bilayer hybrid hydrogel discs on
neuronal cell survival and lesion volume
SubAim 3: Assess the effect of PEGdA/HA-NOG bilayer hybrid hydrogel discs on motor
and cognitive function
Rationale
Traumatic brain injury (TBI) is one of the most prevalent causes of morbidity and
mortality in the United States, with 1.7 million reported cases

342.

Mild cases of TBI

are known as brain concussions and have recently surfaced as one of the most active
research areas due to the high occurrence of cases in popular sports 337,342,343. Many
people suffering from TBI have long lasting effects due to local hypoxia, which can
cause memory loss, inattentiveness, and loss of motor coordination

344–346.

Major

pathological issues stemming from TBI include, disruption of the blood brain barrier,
increased neurotransmitter release, and prolonged neuronal depolarization

336,347–

349. The blood brain barrier plays a crucial role in the systemic delivery of therapeutic
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drugs. It has been determined that 100% of large molecule drugs and 98% of small
molecule drugs cannot pass through alone, necessitating the need for local delivery
350,351.

PEG-based hydrogels are a viable option for local delivery of drugs because of

the biocompatible and non-immunogenic nature of the PEG polymer

97,206,207.

Combined with naturally derived hyaluronic acid polymers, a PEGdA/HA formulation
has potential to be a strong drug delivery system with biocompatible, nonimmunogenic, and bioactive properties 210–212. As previously shown, NOG is capable
of interfering with HIF-1α destabilizing enzymes, causing an increase in HIF-1α
accumulation and subsequent expression of HIF-1α regulated target genes

352,353.

Additionally, by increasing blood microvessel formation through angiogenesis, local
hypoxia due to injury can be alleviated, helping to preserve the surrounding tissue
and reducing the chance of secondary pathologies 11,45,237,272.
In the proposed studies, we aim to achieve sustained, local release of bioactive
NOG from a bilayer hybrid hydrogel to promote angiogenesis, provide
neuroprotection, and improve motor and cognitive function in an in vivo TBI model.
In SubAim 1, we will evaluate the pro-angiogenic effects of released NOG from the
bilayer hybrid hydrogel to assess the ability of NOG to treat ischemic pathologies by
activation of angiogenesis. Using the 6% PEG-bis-AA/0.72% HA-NOG (3.6μg
NOG/0.25mm gel layer) + 6% PEG-bis-AP/0.72% HA-NOG (3.6μg NOG/0.25mm gel
layer) bilayer hybrid hydrogel formulation, a therapeutic dose of ~2.94ug NOG/mL
(>10μM NOG) is expected to be achieved in the injured brain tissue based on studies
performed in Aim 2. The released NOG from the bilayer hybrid hydrogel is expected
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to stabilize and accumulate HIF-1 within injured cells that will begin transcribing
pro-angiogenic target genes to form new blood microvessels and help alleviate local
ischemia. In SubAim 2, we will evaluate the effect of released NOG on neuroprotection
and lesion cavity volume, as we expect that activation of the angiogenic pathway will
reduce neuronal cell death and tissue loss. Neuroprotection will be evaluated by
TUNEL assay and NeuN staining, and lesion volume will be measured after Nissl
staining. In SubAim 3, we will further evaluate the neuroprotective properties of
released NOG on motor and cognitive function to better understand the extent of
rehabilitation stemming from HIF-1α stabilization. We expect that PEG-bis-AP/HANOG + PEG-bis-AA/HA-NOG bilayer hybrid hydrogel can successfully deliver proangiogenic NOG in injured brain tissue to induce angiogenesis, provide
neuroprotection, and improve the motor and cognitive function after injury in a rat
moderate TBI model.
Experimental Design
Surgery
Sprague-Dawley rats (300-350g) will be anesthetized (ketamine/xylazine),
shaved, and placed into a stereotaxic frame. A 6.9mm craniotomy will be performed
at 1mm posterior and 3.5mm lateral to the bregma using a 6.9mm Trephine bur,
removing a 6.9mm section of skull cap without disturbing the dura. The exposed
cortex will be mildly injured by controlled cortical impact (CCI) TBI using a 5mm
impactor tip at 4 m/s velocity, 2mm depth with a 250ms dwell time. After impact, rats
will be sorted into one of the 4 experimental groups listed in Table A.1. The removed
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piece of skull cap will be replaced after treatment and the incision will be sutured
closed. Each group will consist of 12 rats for a total of 48 rats used in the study with
8 rats in each group participating in motor and cognitive assessments before being
sacrificed for histological analysis, while the remaining 4 rats in each group are
sacrificed for PCR analysis after 1 week.

Table A.1. Experimental groups used for CCI TBI in vivo study
Group #
Group 1
Group 2
Group 3
Group 4

Experimental Condition
6% PEG-bis-AA/0.72% HA-NOG + 6% PEG-bis-AP/0.72% HA-NOG
bilayer hybrid hydrogel
6% PEG-bis-AA/0.72% HA + 6% PEG-bis-AP/0.72% HA bilayer hybrid
hydrogel
Untreated TBI (No hydrogel)
Sham

Assess the effect of PEGdA/HA-NOG bilayer hybrid hydrogel discs on HIF-1α
regulated gene expression and angiogenesis
For HIF-1α regulated gene expression analysis, 4 rats from each group will be
sacrificed by CO2 overdose at 7 and 14 days post-TBI and fresh tissue samples will be
collected and processed for gene expression analysis. PCR will be performed using
techniques described in Aim 1 to show changes in expression levels of angiogenic
target genes. Increase in target gene expression will confirm previous results from in
vitro studies in Aims 1 and 2. To further evaluate angiogenesis, rats will be
transcardially perfused, tissue will be collected, sections (10μm) will be mounted, and
antibodies for CD31 (endothelial cell marker) and CD105 (proliferating endothelial
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cell marker) will be applied to evaluate angiogenesis in the injured brain

354–357.

Increases in both CD31 and CD105 will demonstrate increased activity of endothelial
cells and capillary formation by angiogenesis.
Assess the effect of PEGdA/HA-NOG bilayer hybrid hydrogel discs on neuronal
cell survival and lesion volume
At 14 days post-TBI, tissue sections collected from 4 euthanized rats in each
group will be mounted and stained with hematoxylin and eosin (H&E). Nissl stain will
be used to assess lesion cavity volume at the injury site and lesion volume will be
calculated using Cavalieri’s approximation, taking into account distance between
sections, cross-sectional area, number of sections, and section thickness

358,359.

Mounted sections will also be tagged with antibodies for CD68 (macrophage marker)
and NeuN (mature neuronal marker) 360,361. Decreased lesion volume and presence of
CD68 in cells will demonstrate effective wound healing by NOG, while the presence of
NeuN in cells will quantify neuronal cell survival. An increase in NeuN cells will verify
the neuroprotective properties of NOG, as cited in the literature.
Assess the effect of PEGdA/HA-NOG bilayer hybrid hydrogel discs on motor and
cognitive function
8 rats from each group will be given several tasks to complete to evaluate
motor and cognitive abilities before and after surgery 362,363. Prior to surgery, rats will
be trained on a rotarod at 60sec intervals with speeds of 5, 10, 15, and 20rpms for 4
days to establish a baseline for comparison after surgery 362. Rats will be tested with
the same rotarod conditions at days 6 and 7 post-surgery and groups will be
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compared to determine if the release of NOG has improved motor coordination. After
the motor coordination tests are complete, rats will be tested for cognitive function
by completing trials of the Morris Water Maze from days 8 to 14 post-surgery, before
euthanization

363.

Each trial will consist of the rats attempting to locate a platform

within 60sec from various starting positions. Results will be compared between
groups to determine if release of NOG has improved cognitive learning.
Methods
Hybrid Hydrogel Polymerization
Bilayer hybrid hydrogel precursor solutions will consist of 6% PEG-bisAP/0.36% HA-NOG + 6% PEG-bis-AA/0.36% HA-NOG and 6% PEG-bis-AP/0.36% HA
+ 6% PEG-bis-AA/0.36% HA. All precursor solutions will contain Irgacure 2959
radical photoinitiator (0.1% w/v). Hydrogel discs (25μL) will be photopolymerized
between glass coverslips separated by 0.25mm Teflon spacers under UV light for
3min on the PEG-bis-AA layer. Teflon spacers will be increased to 0.5mm and the PEGbis-AP layer will be added to finish polymerizing for 7min.
Surgery
Sprague-Dawley rats (300-350g, male) will be anesthetized using appropriate
dosages of ketamine (80-100 mg/kg) and xylazine (5-10 mg/kg), and head will be
shaved. Prior to surgery, each rat’s head will be placed in a stereotaxic frame (David
Kopf Instruments, Tujunga, CA). An incision will be made in the scalp, the skin was
retracted, and a 6.9mm craniotomy performed between bregma and lambda in the
right hemisphere using Trephine burr with 6.9mm tip. The craniotomy will be
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centered with the stereotaxic coordinates of 1mm posterior and 3.5mm lateral to the
bregma. A 7mm section of skull cap will be carefully removed without disruption of
the underlying dura. The exposed cortex will be subjected to a controlled cortical
impact using a 5mm tip, velocity of 4 m/sec, and depth of 2mm below the surface of
cortex with a dwell time of 250msec (TBI-031, Precision systems and
instrumentation, Fairfax station, VA). Immediately after impact, hemorrhage will be
controlled with GelFoam® Sterile Sponge (Patterson ven generics, Devens, MA). After
impact, the bilayer hybrid hydrogels with/without NOG will be placed at the top of
injury site. Untreated TBI and uninjured sham animals will be used as control groups.
The skull cap will be replaced, and then the scalp will be closed with black silk sutures.
Each group will consist of 8 rats for a total of 32 rats. Rats will be given an appropriate
dosage of buprenorphine (0.1-0.5 mg/kg) after surgery to alleviate any pain.
Motor Coordination Analysis
Prior to surgery, 4 rats from each group will be trained on a Rotamax rotarod
for 4 days to evaluate their motor function

362.

Training on the rotarod will evolve

over the course of the 4-day benchmark testing. On day 4 pre-operation, rats will be
tested twice at 5, 10, 15, and 20rpm for 60 seconds with 60 seconds between trials.
On days 3 and 2 pre-operation, rats will be tested 4 times each day at 10rpm. On day
1 pre-operation, rats will be tested twice at 10, 15, and 20rpm for 60 seconds with 60
seconds between trials. On days 6 and 7 post-surgery, rats will be tested twice at 10,
15, and 20rpm for 60 seconds with 60 seconds between trials. Time-to-fall will be
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recorded for each trial and data for pre-operation and post-operation will be
compared.
Cognitive Function Analysis
Cognitive learning will also be tested 8 days post-surgery using the Morris
Water Maze and Noldus EthoVision XT video tracking system 363. A platform will be
placed 35cm from the wall of the maze and sit 1cm below the waterline. By placing
the platform in the northwest quadrant of the maze, two of the four start positions
(north and west) will be considered “short” starts, while the others (south and east)
will be considered “long” starts. 4 rats from each group will have 60 seconds to reach
the platform on each attempt before being placed onto the platform if they do not
reach it within the time limit. There will be four attempts for each rat per day for five
consecutive days of testing. A sixth day of testing will omit the platform and assess
the rats’ ability to remember the location of the platform. Data collected from these
tests will include time to locate the platform, total distance swam, swimming speed,
time spent in target quadrant, and time spent in outer quadrants.
Angiogenic Gene Expression
Tissue samples will be harvested at the injury site from 4 rats in each group at
days 7 and 14 post-surgery. Harvested samples will be processed to purify desired
genetic material and reverse transcribed to cDNA using techniques described in Aim
1. PCR will be performed with primers for B2M (housekeeping gene), VEGF, GLUT1,
and PHD2 (primer sequences listed in Aim 1).
Histological Analysis
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14 days post-surgery, 4 rats from each group will be anesthetized with 5%
isoflurane,

transcardially

perfused

with

0.9%

saline

followed

by

4%

paraformaldehyde (PFA) to fix the tissue, and immediately decapitated. Brain tissue
will be harvested, stored in 4% PFA at 4°C for 3 days, rinsed, and stored in 30%
sucrose for 3 additional days. Tissue will be embedded in OCT compound by flash
freezing in liquid nitrogen for 10min and stored at -80°C overnight. Sections (10μm)
will be cut using a cryostat microtome (-20°C), mounted onto glass microscope slides,
and dried with acetone. H&E staining will be used for general structural analysis, Nissl
staining will be used to assess the lesion cavity volume, primary antibodies for CD31
(endothelial cell marker), CD105 (proliferative endothelial cell marker), CD68/ED1
(macrophage marker), and NeuN (mature neuronal marker) will be used to assess
angiogenesis and neuroprotection, and a TUNEL assay will be used to detect
apoptosis 358,360,361. Lesion volume will be calculated using Cavalieri’s approximation,
taking into account distance between sections, cross-sectional area, number of
sections, and section thickness

359.

Slides will be viewed under bright-field and

fluorescence microscopy.
Expected Outcomes/Interpretations
Release of the drug in vivo will be enzymatically-driven and is expected to take
up to 1 week for the PEG-bis-AA layer and 2 weeks for complete release from the PEGbis-AP layer

185.

CCI TBI, using the parameters outlined above, is expected cause

moderate injury to the brain without endangering the subjects 364. Behavior analysis
of the rats is expected show an increase in cognitive ability of the PEG-bis-AP/HA-
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NOG + PEG-bis-AA/HA-NOG and PEG-bis-AP/HA + PEG-bis-AA/HA groups when
compared to the control group consisting of no hybrid hydrogel. Despite not being
loaded with the macromolecular prodrug, the PEG-bis-AP/HA + PEG-bis-AA/HA
composition is expected provide enough support for cellular activity to perform
better than the control. It is expected that the PEG-bis-AP/HA-NOG + PEG-bis-AA/HANOG group also have an increase in cognitive ability when compared to the PEG-bisAP/HA + PEG-bis-AA/HA group. The enzymatic release of NOG is expected to have a
two-fold impact on the injury. NOG is expected to increase accumulation of HIF-1α in
cells at the injury site with subsequent increase in angiogenic target gene expression
to quickly form new capillaries for increased blood/nutrient/growth factor delivery
to accelerate wound healing. Sustained activation of HIF-1α is also expected to help
improve motor coordination and cognitive function by increasing neuronal cell
survival. IHC analysis is expected to show a significant increase in angiogenesis and a
significant increase in neuroprotection/neuronal cell survival for the PEG-bisAP/HA-NOG + PEG-bis-AA/HA-NOG group when compared against the PEG-bisAP/HA + PEG-bis-AA/HA and untreated groups.
Potential Complications
During the surgical process, some rats may go into cardiac arrest from
administered anesthetic. If this occurs, cardiopulmonary resuscitation (CPR) will be
performed on the rat for 10 minutes, or until the cardiopulmonary function resumes.
If cardiopulmonary function does not resume, the rat will be removed from testing
and properly discarded. During the behavior analysis, rats may be unwilling to
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perform the task given to them. Based on the personality of the rat, it has been
observed that rats can become timid and refuse to cooperate with testing. Allowing
the rat to rest for 5 minutes and become more familiar with the environment will help
solve this issue. If the uncooperative behavior of the rat persists, the behavior should
be noted but the rat will remain a part of the testing group. Post-surgical
complications, including internal bleeding and infection, may cause adverse events to
occur. If this happens and the rat’s condition does not get better or worsens within
24 hours, the rat will be euthanized. Upon euthanization, brain tissue will be
harvested as normal, and the rat will be dissected to evaluate potential causes.
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